Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7589048,maximum APTT,"The maximum APTT was 83 s (placebo) and 84 s (piroxicam), 3 to 4 h after the start of the infusion, and was comparable on both study days.",Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589048/),s,83,1849,DB00554,Piroxicam
,7589048,maximum APTT,"The maximum APTT was 83 s (placebo) and 84 s (piroxicam), 3 to 4 h after the start of the infusion, and was comparable on both study days.",Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589048/),s,84,1850,DB00554,Piroxicam
,7589048,AUD0-24 (APTT),"The AUD0-24 (APTT) came to 913 s.h.kg-1 under placebo and it was slightly increased to 1,017 s.h.kg-1 after piroxicam; the 95%- confidence interval according to MOSES ranged from 0.97 to 1.24, and the point estimator was 1.10.",Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589048/),[h·s] / [kg],913,1851,DB00554,Piroxicam
,7589048,AUD0-24 (APTT),"The AUD0-24 (APTT) came to 913 s.h.kg-1 under placebo and it was slightly increased to 1,017 s.h.kg-1 after piroxicam; the 95%- confidence interval according to MOSES ranged from 0.97 to 1.24, and the point estimator was 1.10.",Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589048/),[h·s] / [kg],"1,017",1852,DB00554,Piroxicam
,7589048,Bleeding time,Bleeding time was significantly prolonged from 290 s under placebo to 345 s under piroxicam before the start of the infusion of hirudin.,Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589048/),s,290,1853,DB00554,Piroxicam
,7589048,Bleeding time,Bleeding time was significantly prolonged from 290 s under placebo to 345 s under piroxicam before the start of the infusion of hirudin.,Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589048/),s,345,1854,DB00554,Piroxicam
,24954342,T1/2,"Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),h,1.9,2086,DB00554,Piroxicam
,24954342,"Css, muscle/Css","Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),,0.85,2087,DB00554,Piroxicam
,1500446,detection limit,"The detection limit of the assay was 50 ng/ml with intra- and inter-assay coefficients of variation for piroxicam of the order of 2 and 5%, respectively.","Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1500446/),[ng] / [ml],50,7603,DB00554,Piroxicam
,3620272,maximum concentrations,"Similar plasma concentrations were obtained in the two age groups, average maximum concentrations being 39.7 mg l-1 in those under 65 and 38.1 mg l-1 in the elderly.",A comparison of isoxicam pharmacokinetics in young and elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620272/),[mg] / [l],39.7,8885,DB00554,Piroxicam
,3620272,maximum concentrations,"Similar plasma concentrations were obtained in the two age groups, average maximum concentrations being 39.7 mg l-1 in those under 65 and 38.1 mg l-1 in the elderly.",A comparison of isoxicam pharmacokinetics in young and elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620272/),[mg] / [l],38.1,8886,DB00554,Piroxicam
,3620272,half-life,There were no significant differences in the half-life which averaged 30.4 and 32.1 h respectively.,A comparison of isoxicam pharmacokinetics in young and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620272/),h,30.4,8887,DB00554,Piroxicam
,3620272,half-life,There were no significant differences in the half-life which averaged 30.4 and 32.1 h respectively.,A comparison of isoxicam pharmacokinetics in young and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620272/),h,32.1,8888,DB00554,Piroxicam
excess of,3620272,half-life,3 Approximately 9% of all those studied had half-life values in excess of 50 h.,A comparison of isoxicam pharmacokinetics in young and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620272/),h,50,8889,DB00554,Piroxicam
,15907602,pKa1,Piroxicam can be ionized as a zwitterion that has two pKa values (pKa1=1.86 and pKa2=5.46).,Enhanced bioavailability of piroxicam via salt formation with ethanolamines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907602/),,1.86,11357,DB00554,Piroxicam
,15907602,pKa2,Piroxicam can be ionized as a zwitterion that has two pKa values (pKa1=1.86 and pKa2=5.46).,Enhanced bioavailability of piroxicam via salt formation with ethanolamines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907602/),,5.46,11358,DB00554,Piroxicam
over,11853919,Inc,Incorporation efficiencies of over 95% were achieved for the encapsulation.,A floating-type oral dosage form for piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853919/),%,95,14043,DB00554,Piroxicam
,9754983,AUC ratio,"The AUC ratio, (NSAID +omeprazole):NSAID alone, was 1.11, 0.99, and 0.99 for diclofenac, naproxen, and piroxicam, respectively.",Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754983/),,1.11,15134,DB00554,Piroxicam
,9754983,AUC ratio,"The AUC ratio, (NSAID +omeprazole):NSAID alone, was 1.11, 0.99, and 0.99 for diclofenac, naproxen, and piroxicam, respectively.",Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754983/),,0.99,15135,DB00554,Piroxicam
,3762266,elimination half-life,"The elimination half-life of piroxicam after oral administration of droxicam and piroxicam was 8 +/- 2 h in the male rat, 27 +/- 12 h in the female rat and 38 +/- 18 h in the male dog, whilst the half-life of oral absorption of piroxicam did not vary from one animal species to another.",Pharmacokinetics of droxicam in rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3762266/),h,8,16283,DB00554,Piroxicam
,3762266,elimination half-life,"The elimination half-life of piroxicam after oral administration of droxicam and piroxicam was 8 +/- 2 h in the male rat, 27 +/- 12 h in the female rat and 38 +/- 18 h in the male dog, whilst the half-life of oral absorption of piroxicam did not vary from one animal species to another.",Pharmacokinetics of droxicam in rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3762266/),h,27,16284,DB00554,Piroxicam
,3762266,elimination half-life,"The elimination half-life of piroxicam after oral administration of droxicam and piroxicam was 8 +/- 2 h in the male rat, 27 +/- 12 h in the female rat and 38 +/- 18 h in the male dog, whilst the half-life of oral absorption of piroxicam did not vary from one animal species to another.",Pharmacokinetics of droxicam in rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3762266/),h,38,16285,DB00554,Piroxicam
,8148211,Volumes of distribution,Volumes of distribution after the single dose were significantly lower in women compared with men (mean +/- s.d. 10.0 +/- 2.9 l vs 12.9 +/- 5.0 l; 95% confidence interval of the difference 0.1 to 5.6).,The pharmacokinetics of piroxicam in elderly persons with and without renal impairment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148211/),l,10.0,16323,DB00554,Piroxicam
,8148211,Volumes of distribution,Volumes of distribution after the single dose were significantly lower in women compared with men (mean +/- s.d. 10.0 +/- 2.9 l vs 12.9 +/- 5.0 l; 95% confidence interval of the difference 0.1 to 5.6).,The pharmacokinetics of piroxicam in elderly persons with and without renal impairment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148211/),l,12.9,16324,DB00554,Piroxicam
,8148211,Percent unbound piroxicam,4. Percent unbound piroxicam values were 1.46 +/- 0.3% after the single dose and 1.45 +/- 0.2% at steady state.,The pharmacokinetics of piroxicam in elderly persons with and without renal impairment. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148211/),%,1.46,16325,DB00554,Piroxicam
,8148211,Percent unbound piroxicam,4. Percent unbound piroxicam values were 1.46 +/- 0.3% after the single dose and 1.45 +/- 0.2% at steady state.,The pharmacokinetics of piroxicam in elderly persons with and without renal impairment. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148211/),%,1.45,16326,DB00554,Piroxicam
,8148211,half-lives,The half-lives of 5'-hydroxypiroxicam (80.9 +/- 44 h) were significantly longer than those of piroxicam (54.9 +/- 26 h) after chronic dosing.,The pharmacokinetics of piroxicam in elderly persons with and without renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148211/),h,80.9,16327,DB00554,Piroxicam
,8148211,half-lives,The half-lives of 5'-hydroxypiroxicam (80.9 +/- 44 h) were significantly longer than those of piroxicam (54.9 +/- 26 h) after chronic dosing.,The pharmacokinetics of piroxicam in elderly persons with and without renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148211/),h,54.9,16328,DB00554,Piroxicam
,19231841,area under curve (AUC(0-->t),"Pharmacokinetic study showed higher area under curve (AUC(0-->t); microg/mL/h) of 293.78 +/- 2.04 and 321.54 +/- 2.37 with optimized 0.2-D(3)P(7.4) and 0.2-D(4)P(7.4) formulations, respectively, as opposed to 279.11 +/- 1.48 with plain PXM.","Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231841/),[μg] / [h·ml],293.78,22509,DB00554,Piroxicam
,19231841,area under curve (AUC(0-->t),"Pharmacokinetic study showed higher area under curve (AUC(0-->t); microg/mL/h) of 293.78 +/- 2.04 and 321.54 +/- 2.37 with optimized 0.2-D(3)P(7.4) and 0.2-D(4)P(7.4) formulations, respectively, as opposed to 279.11 +/- 1.48 with plain PXM.","Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231841/),[μg] / [h·ml],321.54,22510,DB00554,Piroxicam
,19231841,area under curve (AUC(0-->t),"Pharmacokinetic study showed higher area under curve (AUC(0-->t); microg/mL/h) of 293.78 +/- 2.04 and 321.54 +/- 2.37 with optimized 0.2-D(3)P(7.4) and 0.2-D(4)P(7.4) formulations, respectively, as opposed to 279.11 +/- 1.48 with plain PXM.","Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231841/),[μg] / [h·ml],279.11,22511,DB00554,Piroxicam
,19231841,elimination half-life,"The elimination half-life of the drug encapsulated in the formulation was significantly higher (0.2-D(3)P(7.4), 36.6 and 0.2-D(4)P(7.4), 41.1; h) than that of pure drug (33.7 h; p < 0.005), and the overall elimination rate constant of formulations was also less as compared to free drug (p < 0.005).","Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231841/),h,7.4,22512,DB00554,Piroxicam
,19231841,elimination half-life,"The elimination half-life of the drug encapsulated in the formulation was significantly higher (0.2-D(3)P(7.4), 36.6 and 0.2-D(4)P(7.4), 41.1; h) than that of pure drug (33.7 h; p < 0.005), and the overall elimination rate constant of formulations was also less as compared to free drug (p < 0.005).","Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231841/),h,36.6,22513,DB00554,Piroxicam
,19231841,elimination half-life,"The elimination half-life of the drug encapsulated in the formulation was significantly higher (0.2-D(3)P(7.4), 36.6 and 0.2-D(4)P(7.4), 41.1; h) than that of pure drug (33.7 h; p < 0.005), and the overall elimination rate constant of formulations was also less as compared to free drug (p < 0.005).","Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231841/),h,41.1,22514,DB00554,Piroxicam
,19231841,elimination half-life,"The elimination half-life of the drug encapsulated in the formulation was significantly higher (0.2-D(3)P(7.4), 36.6 and 0.2-D(4)P(7.4), 41.1; h) than that of pure drug (33.7 h; p < 0.005), and the overall elimination rate constant of formulations was also less as compared to free drug (p < 0.005).","Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231841/),h,33.7,22515,DB00554,Piroxicam
,19231841,in,"Pharmacodynamic assessment by rat-paw model of 0.2-D(3)P(7.4) and 0.2-D(4)P(7.4) formulations displayed inhibition levels of 54.21 +/- 1.25% and 59.33 +/- 0.63%, respectively, which are higher than those of plain PXM (41.81 +/- 2.9) formulations, after the sixth hour of administration.","Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231841/),%,54.21,22516,DB00554,Piroxicam
,19231841,in,"Pharmacodynamic assessment by rat-paw model of 0.2-D(3)P(7.4) and 0.2-D(4)P(7.4) formulations displayed inhibition levels of 54.21 +/- 1.25% and 59.33 +/- 0.63%, respectively, which are higher than those of plain PXM (41.81 +/- 2.9) formulations, after the sixth hour of administration.","Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231841/),%,59.33,22517,DB00554,Piroxicam
,19231841,in,"Pharmacodynamic assessment by rat-paw model of 0.2-D(3)P(7.4) and 0.2-D(4)P(7.4) formulations displayed inhibition levels of 54.21 +/- 1.25% and 59.33 +/- 0.63%, respectively, which are higher than those of plain PXM (41.81 +/- 2.9) formulations, after the sixth hour of administration.","Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231841/),,41.81,22518,DB00554,Piroxicam
,1598837,T1/2,"This model provides not only the common pharmacokinetic parameters: T1/2 = 1.12 +/- 0.32 h, V1 = 0.64 +/- 0.12 L, AUC = 34.7 +/- 7.8 micrograms.h-1.ml-1, but also the parameters of enterohepatic circulation of piroxicam: the cycling amount of drug Db = 3.9 +/- 1.4 mg, reabsorption fraction Fb = 0.50 +/- 0.04, reabsorption rate constant Ka = 2.55 +/- 0.50 h-1.",[Pharmacokinetic analysis of enterohepatic circulation of piroxicam in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598837/),h,1.12,25354,DB00554,Piroxicam
,1598837,V1,"This model provides not only the common pharmacokinetic parameters: T1/2 = 1.12 +/- 0.32 h, V1 = 0.64 +/- 0.12 L, AUC = 34.7 +/- 7.8 micrograms.h-1.ml-1, but also the parameters of enterohepatic circulation of piroxicam: the cycling amount of drug Db = 3.9 +/- 1.4 mg, reabsorption fraction Fb = 0.50 +/- 0.04, reabsorption rate constant Ka = 2.55 +/- 0.50 h-1.",[Pharmacokinetic analysis of enterohepatic circulation of piroxicam in rabbits]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598837/),l,0.64,25355,DB00554,Piroxicam
,1598837,AUC,"This model provides not only the common pharmacokinetic parameters: T1/2 = 1.12 +/- 0.32 h, V1 = 0.64 +/- 0.12 L, AUC = 34.7 +/- 7.8 micrograms.h-1.ml-1, but also the parameters of enterohepatic circulation of piroxicam: the cycling amount of drug Db = 3.9 +/- 1.4 mg, reabsorption fraction Fb = 0.50 +/- 0.04, reabsorption rate constant Ka = 2.55 +/- 0.50 h-1.",[Pharmacokinetic analysis of enterohepatic circulation of piroxicam in rabbits]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598837/),[μg] / [h·ml],34.7,25356,DB00554,Piroxicam
,1598837,Db,"This model provides not only the common pharmacokinetic parameters: T1/2 = 1.12 +/- 0.32 h, V1 = 0.64 +/- 0.12 L, AUC = 34.7 +/- 7.8 micrograms.h-1.ml-1, but also the parameters of enterohepatic circulation of piroxicam: the cycling amount of drug Db = 3.9 +/- 1.4 mg, reabsorption fraction Fb = 0.50 +/- 0.04, reabsorption rate constant Ka = 2.55 +/- 0.50 h-1.",[Pharmacokinetic analysis of enterohepatic circulation of piroxicam in rabbits]. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598837/),mg,3.9,25357,DB00554,Piroxicam
,1598837,reabsorption fraction Fb,"This model provides not only the common pharmacokinetic parameters: T1/2 = 1.12 +/- 0.32 h, V1 = 0.64 +/- 0.12 L, AUC = 34.7 +/- 7.8 micrograms.h-1.ml-1, but also the parameters of enterohepatic circulation of piroxicam: the cycling amount of drug Db = 3.9 +/- 1.4 mg, reabsorption fraction Fb = 0.50 +/- 0.04, reabsorption rate constant Ka = 2.55 +/- 0.50 h-1.",[Pharmacokinetic analysis of enterohepatic circulation of piroxicam in rabbits]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598837/),,0.50,25358,DB00554,Piroxicam
,1598837,reabsorption rate constant Ka,"This model provides not only the common pharmacokinetic parameters: T1/2 = 1.12 +/- 0.32 h, V1 = 0.64 +/- 0.12 L, AUC = 34.7 +/- 7.8 micrograms.h-1.ml-1, but also the parameters of enterohepatic circulation of piroxicam: the cycling amount of drug Db = 3.9 +/- 1.4 mg, reabsorption fraction Fb = 0.50 +/- 0.04, reabsorption rate constant Ka = 2.55 +/- 0.50 h-1.",[Pharmacokinetic analysis of enterohepatic circulation of piroxicam in rabbits]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598837/),1/[h],2.55,25359,DB00554,Piroxicam
,27307735,polydispersity index,"Formulation containing poloxamer-stabilized EC-NPs (P188/0.2), having a particle size of 240.26±29.24 nm, polydispersity index of 0.562±0.030, entrapment efficiency of 85.29%±1.57%, and modulated release of PX (88% after 12 hours), was selected as the optimum formulation.",Ethyl cellulose nanoparticles as a platform to decrease ulcerogenic potential of piroxicam: formulation and in vitro/in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27307735/),,0.562,26000,DB00554,Piroxicam
,27307735,entrapment efficiency,"Formulation containing poloxamer-stabilized EC-NPs (P188/0.2), having a particle size of 240.26±29.24 nm, polydispersity index of 0.562±0.030, entrapment efficiency of 85.29%±1.57%, and modulated release of PX (88% after 12 hours), was selected as the optimum formulation.",Ethyl cellulose nanoparticles as a platform to decrease ulcerogenic potential of piroxicam: formulation and in vitro/in vivo evaluation. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27307735/),%,85.29,26001,DB00554,Piroxicam
,11867967,peak plasma drug concentration (C(max)),The pharmacokinetic studies showed peak plasma drug concentration (C(max)) of 48.48 +/- 6.57 microg/ml at 2 h (T(max)) after topical application of 500 mg of meloxicam gel formulation.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),[μg] / [ml],48.48,32035,DB00554,Piroxicam
,11867967,T(max),The pharmacokinetic studies showed peak plasma drug concentration (C(max)) of 48.48 +/- 6.57 microg/ml at 2 h (T(max)) after topical application of 500 mg of meloxicam gel formulation.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),h,2,32036,DB00554,Piroxicam
,11867967,area under the curve,The area under the curve as calculated from 0 to 6 h was found to be 114.18 +/- 4.23 and 194.13 +/- 3.78 microg x h/ml for 0 to infinity.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),[h·μg] / [ml],114.18,32037,DB00554,Piroxicam
,11867967,area under the curve,The area under the curve as calculated from 0 to 6 h was found to be 114.18 +/- 4.23 and 194.13 +/- 3.78 microg x h/ml for 0 to infinity.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),[h·μg] / [ml],194.13,32038,DB00554,Piroxicam
,16032972,flow-rate,A flow-rate of 2 mL/min achieves a complete chromatographic run (including column equilibration) within 12 min.,A non-extracting procedure for the determination of meloxicam in plasma samples by HPLC-diode array detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16032972/),[ml] / [min],2,32479,DB00554,Piroxicam
,2053921,elimination half-life,Tenoxicam is a nonsteroidal antiinflammatory drug with an elimination half-life of 60-80 hours; it is administered once daily.,The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053921/),h,60-80,33905,DB00554,Piroxicam
,2053921,steady-state concentrations,"The mean +/- SD steady-state concentrations in synovial fluid and plasma were 3.9 +/- 1.8 micrograms/ml and 9.2 +/- 3.7 micrograms/ml, respectively, yielding a mean +/- SD synovial fluid: plasma ratio of 0.43 +/- 0.12.",The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053921/),[μg] / [ml],3.9,33906,DB00554,Piroxicam
,2053921,steady-state concentrations,"The mean +/- SD steady-state concentrations in synovial fluid and plasma were 3.9 +/- 1.8 micrograms/ml and 9.2 +/- 3.7 micrograms/ml, respectively, yielding a mean +/- SD synovial fluid: plasma ratio of 0.43 +/- 0.12.",The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053921/),[μg] / [ml],9.2,33907,DB00554,Piroxicam
,2053921,synovial fluid: plasma ratio,"The mean +/- SD steady-state concentrations in synovial fluid and plasma were 3.9 +/- 1.8 micrograms/ml and 9.2 +/- 3.7 micrograms/ml, respectively, yielding a mean +/- SD synovial fluid: plasma ratio of 0.43 +/- 0.12.",The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053921/),,0.43,33908,DB00554,Piroxicam
,2053921,synovial fluid:plasma ratio,"The synovial fluid:plasma ratio of unbound tenoxicam was 0.90 +/- 0.3 (95% confidence interval 0.68-1.11), which was not significantly different from a value of 1 (t = -1.09, P = 0.31).",The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053921/),,0.90,33909,DB00554,Piroxicam
,89124,plasma half-life,"A plasma half-life of approximately 45 hours is observed, permitting the use of single daily doses in therapy.",Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/89124/),h,45,34564,DB00554,Piroxicam
,8786978,total body clearance,They differed primarily in total body clearance which was approximately 16 fold greater for diclofenac (213 ml hr-1 per 250 g) than piroxicam (13 ml hr-1 per 250 g).,Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786978/),[ml] / [h],213,38036,DB00554,Piroxicam
,8786978,total body clearance,They differed primarily in total body clearance which was approximately 16 fold greater for diclofenac (213 ml hr-1 per 250 g) than piroxicam (13 ml hr-1 per 250 g).,Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786978/),[ml] / [h],13,38037,DB00554,Piroxicam
,3221746,t1/2 a,Absorption kinetics of droxicam were delayed with respect to those of piroxicam (t1/2 a = 7.55 h for droxicam and 1.78 h for piroxicam).,Comparative study of the multiple dose pharmacokinetics and the tolerance of a new NSAID (droxicam) versus piroxicam in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221746/),h,7.55,39391,DB00554,Piroxicam
,3221746,t1/2 a,Absorption kinetics of droxicam were delayed with respect to those of piroxicam (t1/2 a = 7.55 h for droxicam and 1.78 h for piroxicam).,Comparative study of the multiple dose pharmacokinetics and the tolerance of a new NSAID (droxicam) versus piroxicam in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221746/),h,1.78,39392,DB00554,Piroxicam
,6336292,plasma clearance,The plasma clearance was low with values ranging from 1.3 to 4.2 ml/min and the volume of distribution Vss was small averaging at 20 to 40% of the total body weight.,Pharmacokinetics of tenoxicam in healthy human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6336292/),[ml] / [min],1.3 to 4.2,41326,DB00554,Piroxicam
,6336292,half-life of elimination from the body,The median half-life of elimination from the body was found to be 72 hours (range 42 to 100 hours).,Pharmacokinetics of tenoxicam in healthy human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6336292/),h,72,41327,DB00554,Piroxicam
exceeded,6336292,fraction bound,At pH 7.4 the fraction bound exceeded 99% but was highly dependent on the pH.,Pharmacokinetics of tenoxicam in healthy human volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6336292/),%,99,41328,DB00554,Piroxicam
,6336292,maximum plasma levels,After oral administration of a 20-mg tablet complete and rapid absorption of the drug was observed with maximum plasma levels of 1.7 to 3.6 micrograms/ml reached within 0.5 to 2 hours.,Pharmacokinetics of tenoxicam in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6336292/),[μg] / [ml],1.7 to 3.6,41329,DB00554,Piroxicam
,18520070,solubility,It had the piroxicam solubility of about 1.87 mg/ml and the amount of ethanol of about 4.37 microg/mg.,Preparation and in vivo evaluation of piroxicam-loaded gelatin microcapsule by spray drying technique. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520070/),[mg] / [ml],1.87,42891,DB00554,Piroxicam
,27473280,Oral bioavailability,"Oral bioavailability in ME-C decreased by 38% after lymphatic transport was blocked by cycloheximide, severer than those in ME-A and ME-B (8% and 34%).",Microemulsions containing long-chain oil ethyl oleate improve the oral bioavailability of piroxicam by increasing drug solubility and lymphatic transportation simultaneously. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473280/),%,8,45611,DB00554,Piroxicam
,27473280,Oral bioavailability,"Oral bioavailability in ME-C decreased by 38% after lymphatic transport was blocked by cycloheximide, severer than those in ME-A and ME-B (8% and 34%).",Microemulsions containing long-chain oil ethyl oleate improve the oral bioavailability of piroxicam by increasing drug solubility and lymphatic transportation simultaneously. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473280/),%,34,45612,DB00554,Piroxicam
,3403105,plasma concentration,The mean plasma concentration of piroxicam at the steady-state was significantly higher in elderly subjects (9.30 +/- 0.69 micrograms/ml mean +/- s.e.) than in younger adults (6.24 +/- 0.58 micrograms/ml mean +/- s.e.).,Pharmacokinetic study on piroxicam at the steady-state in elderly subjects and younger adults after administration of piroxicam beta-cyclodextrin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403105/),[μg] / [ml],9.30,45771,DB00554,Piroxicam
,3403105,plasma concentration,The mean plasma concentration of piroxicam at the steady-state was significantly higher in elderly subjects (9.30 +/- 0.69 micrograms/ml mean +/- s.e.) than in younger adults (6.24 +/- 0.58 micrograms/ml mean +/- s.e.).,Pharmacokinetic study on piroxicam at the steady-state in elderly subjects and younger adults after administration of piroxicam beta-cyclodextrin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403105/),[μg] / [ml],6.24,45772,DB00554,Piroxicam
,3403105,distribution volume,"Even though the distribution volume tended to be lower in elderly subjects (106.37 ml/kg), it did not show substantial differences in the two groups whereas the correlation between clearance and age was significant (p less than 0.05).",Pharmacokinetic study on piroxicam at the steady-state in elderly subjects and younger adults after administration of piroxicam beta-cyclodextrin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403105/),[ml] / [kg],106.37,45773,DB00554,Piroxicam
,2284217,terminal half-life,"After oral as well as intravenous administration, a short terminal half-life of lornoxicam in the range of 4-5 hours was found.",Pharmacokinetics of lornoxicam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2284217/),h,4-5,46766,DB00554,Piroxicam
,8450417,half-lives,"Plasma piroxicam concentrations declined in both age groups in a biexponential fashion, with half-lives of 5.9 +/- 0.7 h (mean +/- SD) in the young rats and 30.6 +/- 9.9 h in the old rats.",Effects of age on the pharmacokinetics of piroxicam in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450417/),h,5.9,47860,DB00554,Piroxicam
,8450417,half-lives,"Plasma piroxicam concentrations declined in both age groups in a biexponential fashion, with half-lives of 5.9 +/- 0.7 h (mean +/- SD) in the young rats and 30.6 +/- 9.9 h in the old rats.",Effects of age on the pharmacokinetics of piroxicam in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450417/),h,30.6,47861,DB00554,Piroxicam
,8450417,Total clearance,"Total clearance in the young rats was 0.048 +/- 0.012 L/h/kg, whereas that in the old rats was 0.021 +/- 0.003 L/h/kg.",Effects of age on the pharmacokinetics of piroxicam in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450417/),[l] / [h·kg],0.048,47862,DB00554,Piroxicam
,8450417,Total clearance,"Total clearance in the young rats was 0.048 +/- 0.012 L/h/kg, whereas that in the old rats was 0.021 +/- 0.003 L/h/kg.",Effects of age on the pharmacokinetics of piroxicam in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450417/),[l] / [h·kg],0.021,47863,DB00554,Piroxicam
,8450417,steady-state volume of distribution,"The steady-state volume of distribution in the young rats was 0.42 +/- 0.05 L/kg, and that in the old rats was 0.56 +/- 0.10 L/kg.",Effects of age on the pharmacokinetics of piroxicam in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450417/),[l] / [kg],0.42,47864,DB00554,Piroxicam
,8450417,steady-state volume of distribution,"The steady-state volume of distribution in the young rats was 0.42 +/- 0.05 L/kg, and that in the old rats was 0.56 +/- 0.10 L/kg.",Effects of age on the pharmacokinetics of piroxicam in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450417/),[l] / [kg],0.56,47865,DB00554,Piroxicam
,8450417,fraction unbound,"Piroxicam is a highly plasma protein-bound drug; the fraction unbound in the young rats was determined to be 0.067 +/- 0.022, and that in the old rats was determined to be 0.134 +/- 0.065, or twice that in the young rats.",Effects of age on the pharmacokinetics of piroxicam in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450417/),,0.067,47866,DB00554,Piroxicam
,8450417,fraction unbound,"Piroxicam is a highly plasma protein-bound drug; the fraction unbound in the young rats was determined to be 0.067 +/- 0.022, and that in the old rats was determined to be 0.134 +/- 0.065, or twice that in the young rats.",Effects of age on the pharmacokinetics of piroxicam in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450417/),,0.134,47867,DB00554,Piroxicam
,8983932,AUC0-->infinity,The pharmacokinetic parameter values (mean +/- RSD) of piroxicam after administration of droxicam alone were: AUC0-->infinity = 125.5 +/- 25.1 micrograms.,A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),μg,125.5,52962,DB00554,Piroxicam
,8983932,Cmax,"h/l, Cmax = 2.08 +/- 19.9 micrograms/l, tmax = 7.08 +/- 36.8 h and t1/2 = 46.3 +/- 27.0 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),[μg] / [l],2.08,52963,DB00554,Piroxicam
,8983932,tmax,"h/l, Cmax = 2.08 +/- 19.9 micrograms/l, tmax = 7.08 +/- 36.8 h and t1/2 = 46.3 +/- 27.0 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),h,7.08,52964,DB00554,Piroxicam
,8983932,t1/2,"h/l, Cmax = 2.08 +/- 19.9 micrograms/l, tmax = 7.08 +/- 36.8 h and t1/2 = 46.3 +/- 27.0 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),h,46.3,52965,DB00554,Piroxicam
,8983932,AUC0-->infinity,"Following administration of droxicam together with the antacid the values obtained for the same parameters were: AUC0-->infinity = 135.1 +/- 24.1 micrograms.h/l. Cmax = 1.85 +/- 23.9 micrograms/l, tmax = 8.17 +/- 34.9 h and t1/2 = 52.0 +/- 22.4 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),[h·μg] / [l],135.1,52966,DB00554,Piroxicam
,8983932,Cmax,"Following administration of droxicam together with the antacid the values obtained for the same parameters were: AUC0-->infinity = 135.1 +/- 24.1 micrograms.h/l. Cmax = 1.85 +/- 23.9 micrograms/l, tmax = 8.17 +/- 34.9 h and t1/2 = 52.0 +/- 22.4 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),[μg] / [l],1.85,52967,DB00554,Piroxicam
,8983932,tmax,"Following administration of droxicam together with the antacid the values obtained for the same parameters were: AUC0-->infinity = 135.1 +/- 24.1 micrograms.h/l. Cmax = 1.85 +/- 23.9 micrograms/l, tmax = 8.17 +/- 34.9 h and t1/2 = 52.0 +/- 22.4 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),h,8.17,52968,DB00554,Piroxicam
,8983932,t1/2,"Following administration of droxicam together with the antacid the values obtained for the same parameters were: AUC0-->infinity = 135.1 +/- 24.1 micrograms.h/l. Cmax = 1.85 +/- 23.9 micrograms/l, tmax = 8.17 +/- 34.9 h and t1/2 = 52.0 +/- 22.4 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),h,52.0,52969,DB00554,Piroxicam
,9115051,elimination half-lives (t 1/2,"The nonsteroidal antiinflammatory drugs (NSAIDs) oxaprozin and piroxicam have long elimination half-lives (t 1/2 approximately 55 hours), permitting once-daily dose regimens.","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,55,55465,DB00554,Piroxicam
,9115051,t1/2,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,53.0,55466,DB00554,Piroxicam
,9115051,t1/2,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,57.4,55467,DB00554,Piroxicam
,9115051,apparent oral clearance,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),[l] / [h],0.139,55468,DB00554,Piroxicam
,9115051,apparent oral clearance,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),[l] / [h],0.121,55469,DB00554,Piroxicam
,9115051,apparent volume of distribution,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),l,10.2,55470,DB00554,Piroxicam
,9115051,apparent volume of distribution,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),l,9.13,55471,DB00554,Piroxicam
,9115051,Post-steady-state apparent t 1/2,Post-steady-state apparent t 1/2 of the total and unbound drugs of approximately 62 hours were similarly prolonged with piroxicam but differed substantially with oxaprozin (50.6 hours [total drug] versus 23.8 hours [unbound drug]).,"Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,62,55472,DB00554,Piroxicam
,9115051,Post-steady-state apparent t 1/2,Post-steady-state apparent t 1/2 of the total and unbound drugs of approximately 62 hours were similarly prolonged with piroxicam but differed substantially with oxaprozin (50.6 hours [total drug] versus 23.8 hours [unbound drug]).,"Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,50.6,55473,DB00554,Piroxicam
,9115051,Post-steady-state apparent t 1/2,Post-steady-state apparent t 1/2 of the total and unbound drugs of approximately 62 hours were similarly prolonged with piroxicam but differed substantially with oxaprozin (50.6 hours [total drug] versus 23.8 hours [unbound drug]).,"Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,23.8,55474,DB00554,Piroxicam
,3329107,elimination half-life,The extraction ratio in the liver is small resulting in a long elimination half-life with a mean of 72 hours.,Overview on the pharmacokinetics of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3329107/),h,72,59113,DB00554,Piroxicam
,3455202,terminal half-lives,The terminal half-lives were found to be 58.1 +/- 2.3 hours after intramuscular administration and 60.2 +/- 2.5 hours after oral dosing.,Pharmacokinetics of intramuscular piroxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455202/),h,58.1,60747,DB00554,Piroxicam
,3455202,terminal half-lives,The terminal half-lives were found to be 58.1 +/- 2.3 hours after intramuscular administration and 60.2 +/- 2.5 hours after oral dosing.,Pharmacokinetics of intramuscular piroxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455202/),h,60.2,60748,DB00554,Piroxicam
,2633925,Cmax,"Following a single dose the Cmax was 0.82 +/- 0.15 micrograms/ml, the Tmax was achieved at 6.1 +/- 3.5 h, the elimination half life was 65.7 +/- 17.6 h, the Clt/F was 2.04 +/- 0.53 ml/min, the Vd/F was 11.0 +/- 1.7 l and the AUC infinity was 86.9 +/- 24.6 mugh/ml, which was similar to results reported in other study from piroxicam (10 mg).",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),[μg] / [ml],0.82,66008,DB00554,Piroxicam
,2633925,Tmax,"Following a single dose the Cmax was 0.82 +/- 0.15 micrograms/ml, the Tmax was achieved at 6.1 +/- 3.5 h, the elimination half life was 65.7 +/- 17.6 h, the Clt/F was 2.04 +/- 0.53 ml/min, the Vd/F was 11.0 +/- 1.7 l and the AUC infinity was 86.9 +/- 24.6 mugh/ml, which was similar to results reported in other study from piroxicam (10 mg).",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),h,6.1,66009,DB00554,Piroxicam
,2633925,elimination half life,"Following a single dose the Cmax was 0.82 +/- 0.15 micrograms/ml, the Tmax was achieved at 6.1 +/- 3.5 h, the elimination half life was 65.7 +/- 17.6 h, the Clt/F was 2.04 +/- 0.53 ml/min, the Vd/F was 11.0 +/- 1.7 l and the AUC infinity was 86.9 +/- 24.6 mugh/ml, which was similar to results reported in other study from piroxicam (10 mg).",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),h,65.7,66010,DB00554,Piroxicam
,2633925,Clt/F,"Following a single dose the Cmax was 0.82 +/- 0.15 micrograms/ml, the Tmax was achieved at 6.1 +/- 3.5 h, the elimination half life was 65.7 +/- 17.6 h, the Clt/F was 2.04 +/- 0.53 ml/min, the Vd/F was 11.0 +/- 1.7 l and the AUC infinity was 86.9 +/- 24.6 mugh/ml, which was similar to results reported in other study from piroxicam (10 mg).",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),[ml] / [min],2.04,66011,DB00554,Piroxicam
,2633925,Vd/F,"Following a single dose the Cmax was 0.82 +/- 0.15 micrograms/ml, the Tmax was achieved at 6.1 +/- 3.5 h, the elimination half life was 65.7 +/- 17.6 h, the Clt/F was 2.04 +/- 0.53 ml/min, the Vd/F was 11.0 +/- 1.7 l and the AUC infinity was 86.9 +/- 24.6 mugh/ml, which was similar to results reported in other study from piroxicam (10 mg).",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),l,11.0,66012,DB00554,Piroxicam
,2633925,AUC infinity,"Following a single dose the Cmax was 0.82 +/- 0.15 micrograms/ml, the Tmax was achieved at 6.1 +/- 3.5 h, the elimination half life was 65.7 +/- 17.6 h, the Clt/F was 2.04 +/- 0.53 ml/min, the Vd/F was 11.0 +/- 1.7 l and the AUC infinity was 86.9 +/- 24.6 mugh/ml, which was similar to results reported in other study from piroxicam (10 mg).",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),[mugh] / [ml],86.9,66013,DB00554,Piroxicam
,2633925,Cmed(ss),"Following multiple doses the Cmed(ss) was 2.06 +/- 0.42 microgram/ml, the Tmax(ss) was 8.2 +/- 6.0 h, the elimination half life was 41.4 +/- 12.4 h, the Clt/F was 3.30 +/- 0.63 ml/min, the Vd/F was 11.8 +/- 4.3 l and the AUC infinity was 52.4 +/- 11.3 mugh/ml.",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),[μg] / [ml],2.06,66014,DB00554,Piroxicam
,2633925,Tmax(ss),"Following multiple doses the Cmed(ss) was 2.06 +/- 0.42 microgram/ml, the Tmax(ss) was 8.2 +/- 6.0 h, the elimination half life was 41.4 +/- 12.4 h, the Clt/F was 3.30 +/- 0.63 ml/min, the Vd/F was 11.8 +/- 4.3 l and the AUC infinity was 52.4 +/- 11.3 mugh/ml.",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),h,8.2,66015,DB00554,Piroxicam
,2633925,elimination half life,"Following multiple doses the Cmed(ss) was 2.06 +/- 0.42 microgram/ml, the Tmax(ss) was 8.2 +/- 6.0 h, the elimination half life was 41.4 +/- 12.4 h, the Clt/F was 3.30 +/- 0.63 ml/min, the Vd/F was 11.8 +/- 4.3 l and the AUC infinity was 52.4 +/- 11.3 mugh/ml.",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),h,41.4,66016,DB00554,Piroxicam
,2633925,Clt/F,"Following multiple doses the Cmed(ss) was 2.06 +/- 0.42 microgram/ml, the Tmax(ss) was 8.2 +/- 6.0 h, the elimination half life was 41.4 +/- 12.4 h, the Clt/F was 3.30 +/- 0.63 ml/min, the Vd/F was 11.8 +/- 4.3 l and the AUC infinity was 52.4 +/- 11.3 mugh/ml.",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),[ml] / [min],3.30,66017,DB00554,Piroxicam
,2633925,Vd/F,"Following multiple doses the Cmed(ss) was 2.06 +/- 0.42 microgram/ml, the Tmax(ss) was 8.2 +/- 6.0 h, the elimination half life was 41.4 +/- 12.4 h, the Clt/F was 3.30 +/- 0.63 ml/min, the Vd/F was 11.8 +/- 4.3 l and the AUC infinity was 52.4 +/- 11.3 mugh/ml.",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),l,11.8,66018,DB00554,Piroxicam
,2633925,AUC infinity,"Following multiple doses the Cmed(ss) was 2.06 +/- 0.42 microgram/ml, the Tmax(ss) was 8.2 +/- 6.0 h, the elimination half life was 41.4 +/- 12.4 h, the Clt/F was 3.30 +/- 0.63 ml/min, the Vd/F was 11.8 +/- 4.3 l and the AUC infinity was 52.4 +/- 11.3 mugh/ml.",Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633925/),[mugh] / [ml],52.4,66019,DB00554,Piroxicam
,3262939,unbound fractions of drug,"The unbound fractions of drug in synovial fluid and plasma were on average 0.015 and 0.011, respectively: not significantly different from each other.",Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3262939/),,0.015,66343,DB00554,Piroxicam
,3262939,unbound fractions of drug,"The unbound fractions of drug in synovial fluid and plasma were on average 0.015 and 0.011, respectively: not significantly different from each other.",Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3262939/),,0.011,66344,DB00554,Piroxicam
,3262939,peak concentrations,"The average peak concentrations of tenoxicam in plasma and synovial fluid were 4.3 and 1.4 micrograms/ml, respectively.",Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3262939/),[μg] / [ml],4.3,66345,DB00554,Piroxicam
,3262939,peak concentrations,"The average peak concentrations of tenoxicam in plasma and synovial fluid were 4.3 and 1.4 micrograms/ml, respectively.",Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3262939/),[μg] / [ml],1.4,66346,DB00554,Piroxicam
,8243500,total plasma clearance,"The average total plasma clearance rose with the increase in fu, between the control (6.3 +/- 2.4 ml/h) and plasmapheretic groups (11.1 +/- 4 ml/h), in accordance with predictions of the 'well-stirred' and 'parallel-tube' models, but no statistically significant differences were found between the two groups, perhaps because of the great interindividual variability associated with this parameter.","Effect of induced hypoalbuminemia on distribution, total clearance and unbound clearance of piroxicam in vivo in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243500/),[ml] / [h],6.3,66648,DB00554,Piroxicam
,8243500,total plasma clearance,"The average total plasma clearance rose with the increase in fu, between the control (6.3 +/- 2.4 ml/h) and plasmapheretic groups (11.1 +/- 4 ml/h), in accordance with predictions of the 'well-stirred' and 'parallel-tube' models, but no statistically significant differences were found between the two groups, perhaps because of the great interindividual variability associated with this parameter.","Effect of induced hypoalbuminemia on distribution, total clearance and unbound clearance of piroxicam in vivo in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243500/),[ml] / [h],11.1,66649,DB00554,Piroxicam
,8243500,total plasma clearance,"The total plasma clearance value of the Ficol group (5.4 +/- 2.2 ml/h) was close to that of the control group, despite the high increase in the unbound fraction in plasma.","Effect of induced hypoalbuminemia on distribution, total clearance and unbound clearance of piroxicam in vivo in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243500/),[ml] / [h],5.4,66650,DB00554,Piroxicam
,3582473,Trough steady-state levels,"Trough steady-state levels of piroxicam and 5'-hydroxypiroxicam were 5.5 and 1.2 micrograms/ml, respectively.",Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582473/),[μg] / [ml],5.5,69518,DB00554,Piroxicam
,3582473,Trough steady-state levels,"Trough steady-state levels of piroxicam and 5'-hydroxypiroxicam were 5.5 and 1.2 micrograms/ml, respectively.",Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582473/),[μg] / [ml],1.2,69519,DB00554,Piroxicam
,3582473,plasma half-life,Piroxicam's plasma half-life (54.9 h) was significantly shorter than that of 5'-hydroxypiroxicam (70.5 h).,Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582473/),h,54.9,69520,DB00554,Piroxicam
,3582473,plasma half-life,Piroxicam's plasma half-life (54.9 h) was significantly shorter than that of 5'-hydroxypiroxicam (70.5 h).,Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582473/),h,70.5,69521,DB00554,Piroxicam
,3582473,Percent unbound,Percent unbound piroxicam and 5'-hydroxypiroxicam in plasma at steady-state averaged 1.10 and 8.07 respectively.,Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582473/),,1.10,69522,DB00554,Piroxicam
,3582473,Percent unbound,Percent unbound piroxicam and 5'-hydroxypiroxicam in plasma at steady-state averaged 1.10 and 8.07 respectively.,Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582473/),,8.07,69523,DB00554,Piroxicam
,3582473,steady-state plasma levels (Css),Average steady-state plasma levels (Css) of piroxicam (7.0 micrograms/ml) were significantly higher than predicted from a previously reported single dose study (5.3 micrograms/ml).,Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582473/),[μg] / [ml],7.0,69524,DB00554,Piroxicam
,3582473,steady-state plasma levels (Css),Average steady-state plasma levels (Css) of piroxicam (7.0 micrograms/ml) were significantly higher than predicted from a previously reported single dose study (5.3 micrograms/ml).,Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582473/),[μg] / [ml],5.3,69525,DB00554,Piroxicam
,15847998,T(lag),T(lag) with freeze-dried tablet was three times shorter than with capsule (21.6 min versus 59.4 min).,Pharmacokinetic profiles of two tablet formulations of piroxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15847998/),min,21.6,72873,DB00554,Piroxicam
,15847998,T(lag),T(lag) with freeze-dried tablet was three times shorter than with capsule (21.6 min versus 59.4 min).,Pharmacokinetic profiles of two tablet formulations of piroxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15847998/),min,59.4,72874,DB00554,Piroxicam
,8162655,elimination half-life,The elimination half-life varies between 30 and 70 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30 and 70,74980,DB00554,Piroxicam
,8162655,oral bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,100,74981,DB00554,Piroxicam
,8162655,bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,80,74982,DB00554,Piroxicam
,8162655,elimination half-life,The mean elimination half-life is 60 to 75 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,60 to 75,74983,DB00554,Piroxicam
,8162655,elimination half-life,The mean elimination half-life is 30 hours and does not appear to be affected by the age of the patient.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30,74984,DB00554,Piroxicam
,8162655,elimination half-life,Lornoxicam differs from other oxicam NSAIDs because it has a short elimination half-life of 3 to 4 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,3 to 4,74985,DB00554,Piroxicam
,8137596,Peak plasma concentrations,Peak plasma concentrations of 2.7 mg/L (range 2.3 to 3.0 mg/L) have been reported in different groups of fasted healthy volunteers 1.9 hours (1.0 to 5.0 hours) after a single oral dose of 20mg.,Clinical pharmacokinetics of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137596/),[mg] / [l],2.7,75868,DB00554,Piroxicam
,8137596,elimination half-life,A mean elimination half-life of 67 hours (49 to 81 hours) has been estimated.,Clinical pharmacokinetics of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137596/),h,67,75869,DB00554,Piroxicam
,8137596,apparent volume of distribution,"A small apparent volume of distribution of 9.6L (7.5 to 11.5L), and low total plasma clearance of 0.106 L/h (0.079 to 0.142 L/h), have been reported in different groups of healthy volunteers after oral and intravenous administration.",Clinical pharmacokinetics of tenoxicam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137596/),l,9.6,75870,DB00554,Piroxicam
,8137596,total plasma clearance,"A small apparent volume of distribution of 9.6L (7.5 to 11.5L), and low total plasma clearance of 0.106 L/h (0.079 to 0.142 L/h), have been reported in different groups of healthy volunteers after oral and intravenous administration.",Clinical pharmacokinetics of tenoxicam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137596/),[l] / [h],0.106,75871,DB00554,Piroxicam
,9781419,flow-rate,The flow-rate was 1 ml/min and the effluent was monitored at 405 nm.,High-performance liquid chromatographic determination of amphotericin B in plasma and tissue. Application to pharmacokinetic and tissue distribution studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9781419/),[ml] / [min],1,77517,DB00554,Piroxicam
,1782984,Cmax,The Cmax for piroxicam ranged from 3.6 to 9.8 (mean 6.6) mg.l-1 and its half-life by log linear computation was 22 to 40 (mean 32.6) h.,Steady state pharmacokinetics of piroxicam in children with rheumatic diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782984/),[mg] / [l],6.6,82660,DB00554,Piroxicam
,1782984,half-life,The Cmax for piroxicam ranged from 3.6 to 9.8 (mean 6.6) mg.l-1 and its half-life by log linear computation was 22 to 40 (mean 32.6) h.,Steady state pharmacokinetics of piroxicam in children with rheumatic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782984/),h,22 to 40,82661,DB00554,Piroxicam
,1782984,half-life,The Cmax for piroxicam ranged from 3.6 to 9.8 (mean 6.6) mg.l-1 and its half-life by log linear computation was 22 to 40 (mean 32.6) h.,Steady state pharmacokinetics of piroxicam in children with rheumatic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782984/),h,32.6,82662,DB00554,Piroxicam
,1782984,volumes of distribution (V/F),"The volumes of distribution (V/F) were 0.12 to 0.25 (mean 0.16) l.kg-1, and the total body clearances (CL/F) were 2.1 to 5.0 (mean 3.4) ml.kg-1.h-1.",Steady state pharmacokinetics of piroxicam in children with rheumatic diseases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782984/),[l] / [kg],0.12 to 0.25,82663,DB00554,Piroxicam
,1782984,volumes of distribution (V/F),"The volumes of distribution (V/F) were 0.12 to 0.25 (mean 0.16) l.kg-1, and the total body clearances (CL/F) were 2.1 to 5.0 (mean 3.4) ml.kg-1.h-1.",Steady state pharmacokinetics of piroxicam in children with rheumatic diseases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782984/),[l] / [kg],0.16,82664,DB00554,Piroxicam
,1782984,total body clearances (CL/F),"The volumes of distribution (V/F) were 0.12 to 0.25 (mean 0.16) l.kg-1, and the total body clearances (CL/F) were 2.1 to 5.0 (mean 3.4) ml.kg-1.h-1.",Steady state pharmacokinetics of piroxicam in children with rheumatic diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782984/),[ml] / [h·kg],2.1 to 5.0,82665,DB00554,Piroxicam
,1782984,total body clearances (CL/F),"The volumes of distribution (V/F) were 0.12 to 0.25 (mean 0.16) l.kg-1, and the total body clearances (CL/F) were 2.1 to 5.0 (mean 3.4) ml.kg-1.h-1.",Steady state pharmacokinetics of piroxicam in children with rheumatic diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782984/),[ml] / [h·kg],3.4,82666,DB00554,Piroxicam
,2095346,elimination half-life,The mean elimination half-life after piroxicam alone was 53.1 h.,Enhanced elimination of piroxicam by administration of activated charcoal or cholestyramine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095346/),h,53.1,83304,DB00554,Piroxicam
,2095346,elimination half-life,Cholestyramine administration at the end of one of the periods reduced the mean elimination half-life of piroxicam from 52.3 h to 27.3 h.,Enhanced elimination of piroxicam by administration of activated charcoal or cholestyramine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095346/),h,52.3,83305,DB00554,Piroxicam
,2095346,elimination half-life,Cholestyramine administration at the end of one of the periods reduced the mean elimination half-life of piroxicam from 52.3 h to 27.3 h.,Enhanced elimination of piroxicam by administration of activated charcoal or cholestyramine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095346/),h,27.3,83306,DB00554,Piroxicam
,8304243,Bioavailability,"Bioavailability studies show that conversion to piroxicam is about 100%, 90%, 70%, and 50% in these four species, respectively.","Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304243/),%,100,83331,DB00554,Piroxicam
,8304243,Bioavailability,"Bioavailability studies show that conversion to piroxicam is about 100%, 90%, 70%, and 50% in these four species, respectively.","Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304243/),%,90,83332,DB00554,Piroxicam
,8304243,Bioavailability,"Bioavailability studies show that conversion to piroxicam is about 100%, 90%, 70%, and 50% in these four species, respectively.","Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304243/),%,70,83333,DB00554,Piroxicam
,8304243,Bioavailability,"Bioavailability studies show that conversion to piroxicam is about 100%, 90%, 70%, and 50% in these four species, respectively.","Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304243/),%,50,83334,DB00554,Piroxicam
,8304243,conversion,"Bioavailability studies show that conversion to piroxicam is about 100%, 90%, 70%, and 50% in these four species, respectively.","Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. ",fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304243/),%,100,83335,DB00554,Piroxicam
,8304243,conversion,"Bioavailability studies show that conversion to piroxicam is about 100%, 90%, 70%, and 50% in these four species, respectively.","Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. ",fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304243/),%,90,83336,DB00554,Piroxicam
,8304243,conversion,"Bioavailability studies show that conversion to piroxicam is about 100%, 90%, 70%, and 50% in these four species, respectively.","Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. ",fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304243/),%,70,83337,DB00554,Piroxicam
,8304243,conversion,"Bioavailability studies show that conversion to piroxicam is about 100%, 90%, 70%, and 50% in these four species, respectively.","Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. ",fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304243/),%,50,83338,DB00554,Piroxicam
,6971114,plasma half-life,"It was found that: the plasma half-life is much longer in man (ca. 35 h) than in rodents (3--5.5 h in the rabbit, 5 h in the rat and mouse).",Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam in rodents and in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6971114/),h,35,88850,DB00554,Piroxicam
,6971114,plasma half-life,"It was found that: the plasma half-life is much longer in man (ca. 35 h) than in rodents (3--5.5 h in the rabbit, 5 h in the rat and mouse).",Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam in rodents and in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6971114/),h,3--5.5,88851,DB00554,Piroxicam
,6971114,plasma half-life,"It was found that: the plasma half-life is much longer in man (ca. 35 h) than in rodents (3--5.5 h in the rabbit, 5 h in the rat and mouse).",Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam in rodents and in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6971114/),h,5,88852,DB00554,Piroxicam
,6971114,intercompartmental t 1/2,A thorough pharmacokinetic analysis in the rabbit revealed a two-compartment distribution of the drug with an intercompartmental t 1/2 0.67 h and an excretion + metabolisation t 1/2 of 3.16 h.,Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam in rodents and in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6971114/),h,0.67,88853,DB00554,Piroxicam
,6971114,excretion + metabolisation t 1/2,A thorough pharmacokinetic analysis in the rabbit revealed a two-compartment distribution of the drug with an intercompartmental t 1/2 0.67 h and an excretion + metabolisation t 1/2 of 3.16 h.,Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam in rodents and in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6971114/),h,3.16,88854,DB00554,Piroxicam
,3877538,half-life,"However, the mean half-life for synovial fluid (45 h) was not significantly different from that for plasma (42 h).",A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877538/),h,45,92345,DB00554,Piroxicam
,3877538,half-life,"However, the mean half-life for synovial fluid (45 h) was not significantly different from that for plasma (42 h).",A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877538/),h,42,92346,DB00554,Piroxicam
,2625372,Cmax,Cmax in the cirrhotic patients was 2.63 micrograms/ml (s.d. = 0.92) and tmax was 2.5 h (s.d. = 0.8).,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),[μg] / [ml],2.63,93509,DB00554,Piroxicam
,2625372,tmax,Cmax in the cirrhotic patients was 2.63 micrograms/ml (s.d. = 0.92) and tmax was 2.5 h (s.d. = 0.8).,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),h,2.5,93510,DB00554,Piroxicam
,2625372,elimination half-life (t1/2),The elimination half-life (t1/2) was 53.0 h (s.d. = 19.0) in the cirrhotic patients and 69.2 h (s.d. = 19.3) in the controls.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),h,53.0,93511,DB00554,Piroxicam
,2625372,elimination half-life (t1/2),The elimination half-life (t1/2) was 53.0 h (s.d. = 19.0) in the cirrhotic patients and 69.2 h (s.d. = 19.3) in the controls.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),h,69.2,93512,DB00554,Piroxicam
,2625372,Area under curve,Area under curve was significantly (p less than 0.05) smaller in the cirrhotic patients (159 micrograms.h/ml; s.d. = 65) than in the controls (254 micrograms.h/ml; s.d. = 92).,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),[h·μg] / [ml],159,93513,DB00554,Piroxicam
,2625372,Area under curve,Area under curve was significantly (p less than 0.05) smaller in the cirrhotic patients (159 micrograms.h/ml; s.d. = 65) than in the controls (254 micrograms.h/ml; s.d. = 92).,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),[h·μg] / [ml],254,93514,DB00554,Piroxicam
,2625372,urinary excretion,The urinary excretion of the 5'-hydroxy metabolite of tenoxicam averaged 21.6% (s.d. = 3.8) of the administered dose in the cirrhotic patients and 22.1% (s.d. = 3.1) in the control subjects.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),%,21.6,93515,DB00554,Piroxicam
,2625372,urinary excretion,The urinary excretion of the 5'-hydroxy metabolite of tenoxicam averaged 21.6% (s.d. = 3.8) of the administered dose in the cirrhotic patients and 22.1% (s.d. = 3.1) in the control subjects.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),%,22.1,93516,DB00554,Piroxicam
,2625372,unbound drug fraction,The unbound drug fraction averaged 0.8% (s.d. = 0.3) in the cirrhotic patients and 0.8% (s.d. = 0.1) in the 12 control subjects who contributed data to this portion of the study.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),%,0.8,93517,DB00554,Piroxicam
,2625372,unbound drug fraction,The unbound drug fraction averaged 0.8% (s.d. = 0.3) in the cirrhotic patients and 0.8% (s.d. = 0.1) in the 12 control subjects who contributed data to this portion of the study.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),%,0.8,93518,DB00554,Piroxicam
,17383864,peak serum piroxicam concentration,"The average peak serum piroxicam concentration (948 ng/ml, which inhibited cox-2 activity) and serum half-life (15.9 h) were similar to that in normal cats.",Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383864/),[ng] / [ml],948,94931,DB00554,Piroxicam
,17383864,serum half-life,"The average peak serum piroxicam concentration (948 ng/ml, which inhibited cox-2 activity) and serum half-life (15.9 h) were similar to that in normal cats.",Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17383864/),h,15.9,94932,DB00554,Piroxicam
,7589053,terminal phase elimination half-life,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),h,19.5,96473,DB00554,Piroxicam
,7589053,terminal phase elimination half-life,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),h,12.7,96474,DB00554,Piroxicam
,7589053,clearance,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),[l] / [h],0.426,96475,DB00554,Piroxicam
,7589053,clearance,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),[l] / [h],0.636,96476,DB00554,Piroxicam
,3317799,half-life,A pharmacokinetic study showed a half-life for tenoxicam of 45 h in synovial fluid when the half-life was 42 h in plasma.,Clinical experience with tenoxicam: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),h,45,101536,DB00554,Piroxicam
,3317799,half-life,A pharmacokinetic study showed a half-life for tenoxicam of 45 h in synovial fluid when the half-life was 42 h in plasma.,Clinical experience with tenoxicam: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),h,42,101537,DB00554,Piroxicam
,3317799,peak plasma levels,A single and multiple oral dose pharmacokinetic study of tenoxicam in the elderly showed no progressive accumulation with peak plasma levels of 2.6 micrograms/ml after the single dose and 12.4 micrograms/ml at steady state.,Clinical experience with tenoxicam: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),[μg] / [ml],2.6,101538,DB00554,Piroxicam
,3317799,peak plasma levels,A single and multiple oral dose pharmacokinetic study of tenoxicam in the elderly showed no progressive accumulation with peak plasma levels of 2.6 micrograms/ml after the single dose and 12.4 micrograms/ml at steady state.,Clinical experience with tenoxicam: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),[μg] / [ml],12.4,101539,DB00554,Piroxicam
,27895468,zeta potential,"PRX-loaded NPs consisting of poly(lactic-co-glycolic acid), Eudragit RL, and polyvinyl alcohol were constructed with the following characteristics: particle size of 220 nm, zeta potential of 11.5 mV in phosphate-buffered saline, and loading amount of 4.0% (w/w) of PRX.",Increased localized delivery of piroxicam by cationic nanoparticles after intra-articular injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27895468/),mv,11.5,102578,DB00554,Piroxicam
,2373127,t 1/2,"Cholestyramine increased piroxicam & tenoxicam elimination approximately 2-fold (t 1/2 50.3 vs 28.1 h and 73.6 vs 35.8 h, respectively).",Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373127/),h,50.3,105018,DB00554,Piroxicam
,2373127,t 1/2,"Cholestyramine increased piroxicam & tenoxicam elimination approximately 2-fold (t 1/2 50.3 vs 28.1 h and 73.6 vs 35.8 h, respectively).",Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373127/),h,28.1,105019,DB00554,Piroxicam
,2373127,t 1/2,"Cholestyramine increased piroxicam & tenoxicam elimination approximately 2-fold (t 1/2 50.3 vs 28.1 h and 73.6 vs 35.8 h, respectively).",Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373127/),h,73.6,105020,DB00554,Piroxicam
,2373127,t 1/2,"Cholestyramine increased piroxicam & tenoxicam elimination approximately 2-fold (t 1/2 50.3 vs 28.1 h and 73.6 vs 35.8 h, respectively).",Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373127/),h,35.8,105021,DB00554,Piroxicam
,6861813,plasma half life,"Following single oral doses of 10 to 100 mg, piroxicam is rapidly and fully absorbed, and eliminated with a mean plasma half life of about 45 hr.",Pharmacokinetics of piroxicam in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861813/),h,45,105048,DB00554,Piroxicam
,6861813,peak concentrations,Mean peak concentrations are about 2 micrograms/ml after single 20 mg doses and about 6 micrograms/ml at steady state with 20 mg daily.,Pharmacokinetics of piroxicam in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861813/),[μg] / [ml],2,105049,DB00554,Piroxicam
,6861813,peak concentrations,Mean peak concentrations are about 2 micrograms/ml after single 20 mg doses and about 6 micrograms/ml at steady state with 20 mg daily.,Pharmacokinetics of piroxicam in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861813/),[μg] / [ml],6,105050,DB00554,Piroxicam
,2778095,Cmax,The pharmacokinetic parameters of droxicam were: Cmax = 1.03 +/- 0.16 micrograms/mL (mean +/- SD).,The influence of gastric emptying on droxicam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[μg] / [ml],1.03,107248,DB00554,Piroxicam
,2778095,Tmax,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,11.1,107249,DB00554,Piroxicam
,2778095,AUC,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[h·μg] / [ml],115.7,107250,DB00554,Piroxicam
,2778095,T 1/2 a,"Tmax = 11.1 +/- 5.7 hr, AUC = 115.7 +/- 29.6 micrograms hr/mL, T 1/2 a = 2.64 +/- 0.72 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,2.64,107251,DB00554,Piroxicam
,2778095,T 1/2 el,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,73.6,107252,DB00554,Piroxicam
,2778095,CL/F,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),[ml] / [min],3.06,107253,DB00554,Piroxicam
,2778095,MRT,"T 1/2 el = 73.6 +/- 16.7 hr, CL/F = 3.06 +/- 0.80 mL/min and MRT = 111.1 +/- 23.5 hr.",The influence of gastric emptying on droxicam pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,111.1,107254,DB00554,Piroxicam
,2778095,Tmax,"Following modification of gastric emptying, only Tmax (droxicam + metoclopramide = 25.0 +/- 10.8 hr and droxicam + propantheline = 20.8 +/- 8.8 hr) underwent significant change (P less than 0.05).",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,25.0,107255,DB00554,Piroxicam
,2778095,Tmax,"Following modification of gastric emptying, only Tmax (droxicam + metoclopramide = 25.0 +/- 10.8 hr and droxicam + propantheline = 20.8 +/- 8.8 hr) underwent significant change (P less than 0.05).",The influence of gastric emptying on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778095/),h,20.8,107256,DB00554,Piroxicam
,1499594,14C,Total plasma radioactivity peaked between 8 and 24 h postdose with mean 14C plasma radioactivity half-life of 36.1 h.,Metabolic disposition of the non-steroidal anti-inflammatory agent isoxicam in man. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499594/),h,36.1,108762,DB00554,Piroxicam
,1499594,plasma radioactivity half-life,Total plasma radioactivity peaked between 8 and 24 h postdose with mean 14C plasma radioactivity half-life of 36.1 h.,Metabolic disposition of the non-steroidal anti-inflammatory agent isoxicam in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499594/),h,36.1,108763,DB00554,Piroxicam
,7788170,Plasma protein binding,Plasma protein binding ranged from 25 to 55%.,"Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7788170/),%,25 to 55,113592,DB00554,Piroxicam
,7788170,Total clearance,"Total clearance of MTX was not statistically different with piroxicam (8.0 l/h for total MTX, 13.7 l/h for free MTX) vs without piroxicam.","Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7788170/),[l] / [h],8.0,113593,DB00554,Piroxicam
,7788170,Total clearance,"Total clearance of MTX was not statistically different with piroxicam (8.0 l/h for total MTX, 13.7 l/h for free MTX) vs without piroxicam.","Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7788170/),[l] / [h],13.7,113594,DB00554,Piroxicam
,6342955,half-life,"Plasma concentrations of tilcotil showed that the drug's half-life was approximately 50 hours, compatible with once daily dosage, and steady state concentrations on multiple dosing were reached after 10 to 12 days.",Gastro-intestinal blood loss with high dose tilcotil (Ro 12-0068) and aspirin: an open crossover clinical trial and pharmacokinetic assessment in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342955/),h,50,114992,DB00554,Piroxicam
,12039643,retention time,"The retention time observed for meloxicam and piroxicam (internal standard) were at 6.0 and 4.0 min, respectively.",LC determination and pharmacokinetics of meloxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12039643/),min,6.0,117429,DB00554,Piroxicam
,12039643,retention time,"The retention time observed for meloxicam and piroxicam (internal standard) were at 6.0 and 4.0 min, respectively.",LC determination and pharmacokinetics of meloxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12039643/),min,4.0,117430,DB00554,Piroxicam
,1361533,unbound fraction,"As a result of this decrease, the unbound fraction of tenoxicam in uraemic rats (0.06 +/- 0.02) and in anephric rats (0.11 +/- 0.08) increased with respect to the control group (0.03 +/- 0.004).",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),,0.06,119684,DB00554,Piroxicam
,1361533,unbound fraction,"As a result of this decrease, the unbound fraction of tenoxicam in uraemic rats (0.06 +/- 0.02) and in anephric rats (0.11 +/- 0.08) increased with respect to the control group (0.03 +/- 0.004).",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),,0.11,119685,DB00554,Piroxicam
,1361533,unbound fraction,"As a result of this decrease, the unbound fraction of tenoxicam in uraemic rats (0.06 +/- 0.02) and in anephric rats (0.11 +/- 0.08) increased with respect to the control group (0.03 +/- 0.004).",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),,0.03,119686,DB00554,Piroxicam
,1361533,Vdss,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),ml,55,119687,DB00554,Piroxicam
,1361533,Vdss,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),ml,69,119688,DB00554,Piroxicam
,1361533,Vdss,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),ml,96,119689,DB00554,Piroxicam
,1361533,CL,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),[ml] / [h],7,119690,DB00554,Piroxicam
,1361533,CL,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),[ml] / [h],12,119691,DB00554,Piroxicam
,1361533,CL,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),[ml] / [h],15,119692,DB00554,Piroxicam
less,1361533,extraction ratio,"Tenoxicam elimination was found to be restrictive, with an extraction ratio less than 0.1 in the three groups.",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),,0.1,119693,DB00554,Piroxicam
,1361533,intrinsic clearance,"The induction of nephrotic syndrome was observed to have a significant effect on intrinsic metabolic activity, intrinsic clearance of tenoxicam being reduced by 30% in the anephric rats (161 +/- 38 mL h-1) with respect to the values obtained in the control group (228 +/- 22 mL h-1).",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),[ml] / [h],161,119694,DB00554,Piroxicam
,1361533,intrinsic clearance,"The induction of nephrotic syndrome was observed to have a significant effect on intrinsic metabolic activity, intrinsic clearance of tenoxicam being reduced by 30% in the anephric rats (161 +/- 38 mL h-1) with respect to the values obtained in the control group (228 +/- 22 mL h-1).",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),[ml] / [h],228,119695,DB00554,Piroxicam
,10428018,time of peak concentration,The time of peak concentration value for complexed piroxicam was 5.27 hr compared to only 2.56 hr for the uncomplexed agent.,Pharmacokinetic profile and adverse gastric effect of zinc-piroxicam in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428018/),h,5.27,121887,DB00554,Piroxicam
,10428018,time of peak concentration,The time of peak concentration value for complexed piroxicam was 5.27 hr compared to only 2.56 hr for the uncomplexed agent.,Pharmacokinetic profile and adverse gastric effect of zinc-piroxicam in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428018/),h,2.56,121888,DB00554,Piroxicam
,7986242,Cmax,"Plasma peak concentrations appeared highest after the commercial tablet (mean +/- SD: Cmax 2.8 +/- 0.55 mg/l), but the difference to the effervescent tablet (2.7 +/- 0.41 mg/l) and the milk formulation (2.5 +/- 0.41 mg/l) was negligible.",Relative bioavailability of oral dosage forms of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),[mg] / [l],2.8,121929,DB00554,Piroxicam
,7986242,Cmax,"Plasma peak concentrations appeared highest after the commercial tablet (mean +/- SD: Cmax 2.8 +/- 0.55 mg/l), but the difference to the effervescent tablet (2.7 +/- 0.41 mg/l) and the milk formulation (2.5 +/- 0.41 mg/l) was negligible.",Relative bioavailability of oral dosage forms of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),[mg] / [l],2.7,121930,DB00554,Piroxicam
,7986242,Cmax,"Plasma peak concentrations appeared highest after the commercial tablet (mean +/- SD: Cmax 2.8 +/- 0.55 mg/l), but the difference to the effervescent tablet (2.7 +/- 0.41 mg/l) and the milk formulation (2.5 +/- 0.41 mg/l) was negligible.",Relative bioavailability of oral dosage forms of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),[mg] / [l],2.5,121931,DB00554,Piroxicam
,7986242,elimination half-lives,"Similar mean elimination half-lives of 73, 77, and 77 h were obtained with the effervescent tablet, the milk drink, and the commercial tablet, respectively.",Relative bioavailability of oral dosage forms of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),h,73,121932,DB00554,Piroxicam
,7986242,elimination half-lives,"Similar mean elimination half-lives of 73, 77, and 77 h were obtained with the effervescent tablet, the milk drink, and the commercial tablet, respectively.",Relative bioavailability of oral dosage forms of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),h,77,121933,DB00554,Piroxicam
,7986242,bioavailability,Average bioavailability relative to the tablet was for the effervescent tablet and for the milk drink 96% with a coefficient of variation of 8%.,Relative bioavailability of oral dosage forms of tenoxicam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),%,96,121934,DB00554,Piroxicam
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],527.00,122561,DB00554,Piroxicam
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],269. 45,122562,DB00554,Piroxicam
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],258.65,122563,DB00554,Piroxicam
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],243.22,122564,DB00554,Piroxicam
,10606790,AUC,The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h.,The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606790/),[μg] / [h·ml],88.09,122565,DB00554,Piroxicam
,17703745,recoveries,"The recoveries of lornoxicam and isoxicam were 87.8% and 66.5%, respectively.",Liquid chromatography-electrospray ionization tandem mass spectrometric determination of lornoxicam in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17703745/),%,87.8,122603,DB00554,Piroxicam
,17703745,recoveries,"The recoveries of lornoxicam and isoxicam were 87.8% and 66.5%, respectively.",Liquid chromatography-electrospray ionization tandem mass spectrometric determination of lornoxicam in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17703745/),%,66.5,122604,DB00554,Piroxicam
,10445485,limit of detection (LOD),"The urinary tenoxicam limit of detection (LOD) and limit of quantitation (LOQ) were 0.3 and 0.4 microg/mL, respectively.",The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[μg] / [ml],0.3,123140,DB00554,Piroxicam
,10445485,limit of quantitation (LOQ),"The urinary tenoxicam limit of detection (LOD) and limit of quantitation (LOQ) were 0.3 and 0.4 microg/mL, respectively.",The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[μg] / [ml],0.4,123141,DB00554,Piroxicam
,10445485,LOD,"The urinary hydroxytenoxicam LOD and LOQ were 0.6 and 0.8 microg/mL, respectively.",The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[μg] / [ml],0.6,123142,DB00554,Piroxicam
,10445485,LOQ,"The urinary hydroxytenoxicam LOD and LOQ were 0.6 and 0.8 microg/mL, respectively.",The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[μg] / [ml],0.8,123143,DB00554,Piroxicam
,10445485,peak average concentration,The peak average concentration was 434.5 ng/mL at 3 h.,The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[ng] / [ml],434.5,123144,DB00554,Piroxicam
,10445485,LOD,The serum tenoxicam LOD and LOQ were 5.7 and 7.3 ng/mL.,The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[ng] / [ml],5.7,123145,DB00554,Piroxicam
,10445485,LOQ,The serum tenoxicam LOD and LOQ were 5.7 and 7.3 ng/mL.,The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[ng] / [ml],7.3,123146,DB00554,Piroxicam
,15229460,area under the plasma concentration-time curve (AUC) from time 0 to infinity,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],190,123471,DB00554,Piroxicam
,15229460,area under the plasma concentration-time curve (AUC) from time 0 to infinity,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],261,123472,DB00554,Piroxicam
,15229460,area under the plasma concentration-time curve (AUC) from time 0 to infinity,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],335,123473,DB00554,Piroxicam
,15229460,oral clearance,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[ml] / [h],113,123474,DB00554,Piroxicam
,15229460,oral clearance,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[ml] / [h],77,123475,DB00554,Piroxicam
,15229460,oral clearance,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],335,123476,DB00554,Piroxicam
,15229460,oral clearance,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[ml] / [h],67,123477,DB00554,Piroxicam
,15229460,minimum plasma (trough) tenoxicam concentration (Cmin,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[μg] / [ml],5.2,123478,DB00554,Piroxicam
,15229460,minimum plasma (trough) tenoxicam concentration (Cmin,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[μg] / [ml],7.6,123479,DB00554,Piroxicam
,15229460,maximum tenoxicam plasma concentration (Cmax,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[μg] / [ml],7.4,123480,DB00554,Piroxicam
,15229460,maximum tenoxicam plasma concentration (Cmax,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[μg] / [ml],10.5,123481,DB00554,Piroxicam
,15229460,AUC,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],152,123482,DB00554,Piroxicam
,15229460,AUC,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],219,123483,DB00554,Piroxicam
greater,20346740,recovery,SPE recovery of the analytes from plasma and urine was comparable and greater than 80%.,Capillary zone electrophoresis method for determination of (+)-S clopidogrel carboxylic acid metabolite in human plasma and urine designed for biopharmaceutic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20346740/),%,80,127016,DB00554,Piroxicam
,8444358,time-to-peak,The tenoxicam kinetics in these ocular fluids followed that in plasma with the time-to-peak shifted to higher values in the vitreous (1 h) as compared to that in the aqueous and plasma (40 min).,Intraocular and plasma kinetics of tenoxicam in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8444358/),h,1,127768,DB00554,Piroxicam
,8444358,time-to-peak,The tenoxicam kinetics in these ocular fluids followed that in plasma with the time-to-peak shifted to higher values in the vitreous (1 h) as compared to that in the aqueous and plasma (40 min).,Intraocular and plasma kinetics of tenoxicam in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8444358/),min,40,127769,DB00554,Piroxicam
,8444358,AUC,AUC was also higher in the vitreous (10.4 micrograms.h/ml) than in the aqueous humor (2.8 micrograms.h/ml).,Intraocular and plasma kinetics of tenoxicam in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8444358/),[h·μg] / [ml],10.4,127770,DB00554,Piroxicam
,8444358,AUC,AUC was also higher in the vitreous (10.4 micrograms.h/ml) than in the aqueous humor (2.8 micrograms.h/ml).,Intraocular and plasma kinetics of tenoxicam in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8444358/),[h·μg] / [ml],2.8,127771,DB00554,Piroxicam
,3965234,apparent volume of distribution,The apparent volume of distribution was smaller in elderly women (7.8 +/- 0.4 l) than in young men (11.3 +/- 0.3 l) and elderly men (10.8 +/- 0.8 l).,Effects of age and sex on piroxicam disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),l,7.8,129729,DB00554,Piroxicam
,3965234,apparent volume of distribution,The apparent volume of distribution was smaller in elderly women (7.8 +/- 0.4 l) than in young men (11.3 +/- 0.3 l) and elderly men (10.8 +/- 0.8 l).,Effects of age and sex on piroxicam disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),l,11.3,129730,DB00554,Piroxicam
,3965234,apparent volume of distribution,The apparent volume of distribution was smaller in elderly women (7.8 +/- 0.4 l) than in young men (11.3 +/- 0.3 l) and elderly men (10.8 +/- 0.8 l).,Effects of age and sex on piroxicam disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),l,10.8,129731,DB00554,Piroxicam
,3965234,Plasma protein binding,Plasma protein binding of piroxicam ranged from 98.90% to 99.54% bound and was not affected by age or sex.,Effects of age and sex on piroxicam disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),%,98.90,129732,DB00554,Piroxicam
,3965234,Plasma protein binding,Plasma protein binding of piroxicam ranged from 98.90% to 99.54% bound and was not affected by age or sex.,Effects of age and sex on piroxicam disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),%,99.54,129733,DB00554,Piroxicam
,3965234,body clearance,Piroxicam body clearance in elderly women (0.026 +/- 0.002 ml/min/kg) was approximately 33% lower than in young women (0.039 +/- 0.003 ml/min/kg).,Effects of age and sex on piroxicam disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),[ml] / [kg·min],0.026,129734,DB00554,Piroxicam
,3965234,body clearance,Piroxicam body clearance in elderly women (0.026 +/- 0.002 ml/min/kg) was approximately 33% lower than in young women (0.039 +/- 0.003 ml/min/kg).,Effects of age and sex on piroxicam disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),[ml] / [kg·min],0.039,129735,DB00554,Piroxicam
,3965234,t1/2s,This difference was reflected in different t1/2s of 61.7 and 44.9 hr.,Effects of age and sex on piroxicam disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),h,61.7,129736,DB00554,Piroxicam
,3965234,t1/2s,This difference was reflected in different t1/2s of 61.7 and 44.9 hr.,Effects of age and sex on piroxicam disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),h,44.9,129737,DB00554,Piroxicam
,3965234,steady-state plasma piroxicam concentrations,"Predicted steady-state plasma piroxicam concentrations were 5.7 micrograms/ml in young women, 5.4 micrograms/ml in young men, 5.7 micrograms/ml in elderly men, and 9.3 micrograms/ml in elderly women.",Effects of age and sex on piroxicam disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),[μg] / [ml],5.7,129738,DB00554,Piroxicam
,3965234,steady-state plasma piroxicam concentrations,"Predicted steady-state plasma piroxicam concentrations were 5.7 micrograms/ml in young women, 5.4 micrograms/ml in young men, 5.7 micrograms/ml in elderly men, and 9.3 micrograms/ml in elderly women.",Effects of age and sex on piroxicam disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),[μg] / [ml],5.4,129739,DB00554,Piroxicam
,3965234,steady-state plasma piroxicam concentrations,"Predicted steady-state plasma piroxicam concentrations were 5.7 micrograms/ml in young women, 5.4 micrograms/ml in young men, 5.7 micrograms/ml in elderly men, and 9.3 micrograms/ml in elderly women.",Effects of age and sex on piroxicam disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965234/),[μg] / [ml],9.3,129740,DB00554,Piroxicam
,1807089,Minimal detectable concentration,Minimal detectable concentration of serum piroxicam by using HPLC reported in literature was mostly around 50 ng.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,50,135527,DB00554,Piroxicam
,1807089,detection limit,"A new HPLC method providing a detection limit of 0.75 ng, sensitive enough to quantify low concentrations of serum piroxicam down to 5 ng.",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,0.75,135528,DB00554,Piroxicam
,1807089,flow rate,A mixture of methanol and ammonium acetate 0.1 mol.L-1 (1:0.9 vol.vol-1) was selected as mobile phase with a flow rate of 1 ml.min-1. 0.025% tetramethyl ethylene diamine was added to ammonium acetate solution and adjusted to pH 4.5 with citric acid before mixing.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ml] / [min],1,135529,DB00554,Piroxicam
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),%,96.0-102.4,135530,DB00554,Piroxicam
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ng] / [ml],"10-5,000",135531,DB00554,Piroxicam
less,3552584,Volume of distribution,Volume of distribution is mostly low (less than 0.2 L/kg) and protein binding is high (usually 95 to 99%).,Non-steroidal anti-inflammatory analgesics other than salicylates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),[l] / [kg],0.2,136228,DB00554,Piroxicam
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,2 to 5,136229,DB00554,Piroxicam
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,20,136230,DB00554,Piroxicam
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,10,136231,DB00554,Piroxicam
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,12-15,136232,DB00554,Piroxicam
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,16,136233,DB00554,Piroxicam
,3552584,half-life,"Piroxicam has the longest half-life, averaging 45 hours.",Non-steroidal anti-inflammatory analgesics other than salicylates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,45,136234,DB00554,Piroxicam
,16198655,area under the plasma concentration-time curve from time 0 to infinity,Piroxicam's area under the plasma concentration-time curve from time 0 to infinity and oral clearance corrected for body weight were 154+/-37 microg.,Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198655/),μg,154,136418,DB00554,Piroxicam
,16198655,area above the,"The formation of TXB2, reflecting cyclooxygenase type 1 activity, showed significant differences in the area above the effect-time curves (expressed as percent of baseline TXB2.h) between CYP2C9*1/*1 (10,190 +/- 2632) and either CYP2C9*1/*2 (19,255+/-1,291 [P=.00003]) or CYP2C9*1/*3 (18,241+/- 2397 [P=.00003]).",Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198655/),,"10,190",136419,DB00554,Piroxicam
,16198655,area above the,"The formation of TXB2, reflecting cyclooxygenase type 1 activity, showed significant differences in the area above the effect-time curves (expressed as percent of baseline TXB2.h) between CYP2C9*1/*1 (10,190 +/- 2632) and either CYP2C9*1/*2 (19,255+/-1,291 [P=.00003]) or CYP2C9*1/*3 (18,241+/- 2397 [P=.00003]).",Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198655/),,"19,255",136420,DB00554,Piroxicam
,16198655,area above the,"The formation of TXB2, reflecting cyclooxygenase type 1 activity, showed significant differences in the area above the effect-time curves (expressed as percent of baseline TXB2.h) between CYP2C9*1/*1 (10,190 +/- 2632) and either CYP2C9*1/*2 (19,255+/-1,291 [P=.00003]) or CYP2C9*1/*3 (18,241+/- 2397 [P=.00003]).",Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198655/),,"18,241",136421,DB00554,Piroxicam
,3172091,steady state plasma concentration (Css),"The mean piroxicam steady state plasma concentration (Css) averaged 9.2 +/- 4.4 micrograms/ml, the majority of which was highly protein bound (1.4 +/- 0.5% unbound).",The effect of age on piroxicam disposition in rheumatoid arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3172091/),[μg] / [ml],9.2,140536,DB00554,Piroxicam
,3172091,Total plasma clearance (CL/F),Total plasma clearance (CL/F) of piroxicam was 1.85 +/- 0.81 ml/min and the half life (t1/2) was 53.0 +/- 24.2 h.,The effect of age on piroxicam disposition in rheumatoid arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3172091/),[ml] / [min],1.85,140537,DB00554,Piroxicam
,3172091,half life (t1/2),Total plasma clearance (CL/F) of piroxicam was 1.85 +/- 0.81 ml/min and the half life (t1/2) was 53.0 +/- 24.2 h.,The effect of age on piroxicam disposition in rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3172091/),h,53.0,140538,DB00554,Piroxicam
,19224373,solubility,"The volume ratio of 5:4:1 in the DMSO/polyethoxylated castor oil/ethanol system resulted in a more suitable vehicle than other systems, with a high solubility (20.73 mg/ml) and low viscosity (10.0 Cp).",Improving tenoxicam solubility and bioavailability by cosolvent system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19224373/),[mg] / [ml],20.73,144017,DB00554,Piroxicam
,27371394,Entrapment efficiency,"Entrapment efficiency of DNR and LNX was 93.16 and 88.59 %, respectively.","Lecithin and PLGA-based self-assembled nanocomposite, Lecithmer: preparation, characterization, and pharmacokinetic/pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27371394/),%,93.16,144579,DB00554,Piroxicam
,27371394,Entrapment efficiency,"Entrapment efficiency of DNR and LNX was 93.16 and 88.59 %, respectively.","Lecithin and PLGA-based self-assembled nanocomposite, Lecithmer: preparation, characterization, and pharmacokinetic/pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27371394/),%,88.59,144580,DB00554,Piroxicam
,27371394,elimination rate constant,"Pharmacokinetic study in Wistar rats with i.v. administered DNR-loaded Lecithmer showed higher volume of distribution, lower elimination rate constant, and longer half-life (81.68 L, 0.3535 h(-1), 1.96 h) as compared to DNR solution (57.46 L, 0.4237 h(-1), 1.635 h).","Lecithin and PLGA-based self-assembled nanocomposite, Lecithmer: preparation, characterization, and pharmacokinetic/pharmacodynamic evaluation. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27371394/),1/[h],0.3535,144581,DB00554,Piroxicam
,27371394,elimination rate constant,"Pharmacokinetic study in Wistar rats with i.v. administered DNR-loaded Lecithmer showed higher volume of distribution, lower elimination rate constant, and longer half-life (81.68 L, 0.3535 h(-1), 1.96 h) as compared to DNR solution (57.46 L, 0.4237 h(-1), 1.635 h).","Lecithin and PLGA-based self-assembled nanocomposite, Lecithmer: preparation, characterization, and pharmacokinetic/pharmacodynamic evaluation. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27371394/),l,57.46,144582,DB00554,Piroxicam
,27371394,half-life,"Pharmacokinetic study in Wistar rats with i.v. administered DNR-loaded Lecithmer showed higher volume of distribution, lower elimination rate constant, and longer half-life (81.68 L, 0.3535 h(-1), 1.96 h) as compared to DNR solution (57.46 L, 0.4237 h(-1), 1.635 h).","Lecithin and PLGA-based self-assembled nanocomposite, Lecithmer: preparation, characterization, and pharmacokinetic/pharmacodynamic evaluation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27371394/),h,1.96,144583,DB00554,Piroxicam
,27371394,half-life,"Pharmacokinetic study in Wistar rats with i.v. administered DNR-loaded Lecithmer showed higher volume of distribution, lower elimination rate constant, and longer half-life (81.68 L, 0.3535 h(-1), 1.96 h) as compared to DNR solution (57.46 L, 0.4237 h(-1), 1.635 h).","Lecithin and PLGA-based self-assembled nanocomposite, Lecithmer: preparation, characterization, and pharmacokinetic/pharmacodynamic evaluation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27371394/),h,1.635,144584,DB00554,Piroxicam
,27371394,maximum inhibition,Pharmacodynamic evaluation of orally administered LNX-loaded Lecithmer showed superior anti-inflammatory activity with maximum inhibition of 81.2 % vis-à-vis 53.57 % in case of LNX suspension.,"Lecithin and PLGA-based self-assembled nanocomposite, Lecithmer: preparation, characterization, and pharmacokinetic/pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27371394/),%,81.2,144585,DB00554,Piroxicam
,27371394,maximum inhibition,Pharmacodynamic evaluation of orally administered LNX-loaded Lecithmer showed superior anti-inflammatory activity with maximum inhibition of 81.2 % vis-à-vis 53.57 % in case of LNX suspension.,"Lecithin and PLGA-based self-assembled nanocomposite, Lecithmer: preparation, characterization, and pharmacokinetic/pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27371394/),%,53.57,144586,DB00554,Piroxicam
,8054251,oral clearance (CLo),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],11.0,145184,DB00554,Piroxicam
,8054251,renal clearance (CLR),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],7.9,145185,DB00554,Piroxicam
,8054251,percent excreted unchanged,"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),%,72,145186,DB00554,Piroxicam
,8054251,fraction unbound (fu),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),,0.54,145187,DB00554,Piroxicam
,16342679,C(max),"After a single oral dose of 2.5 mg glibenclamide, C(max) was (70.0 +/- 11.5) microg x L(-1) in CYP2C9 * 1/ * 3 subjects and (51.9 +/- 12.3) microg x L(-1) in * 1/ *1 subjects.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[μg] / [l],70.0,145409,DB00554,Piroxicam
,16342679,C(max),"After a single oral dose of 2.5 mg glibenclamide, C(max) was (70.0 +/- 11.5) microg x L(-1) in CYP2C9 * 1/ * 3 subjects and (51.9 +/- 12.3) microg x L(-1) in * 1/ *1 subjects.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[μg] / [l],51.9,145410,DB00554,Piroxicam
,16342679,AUC(0-infinity),"AUC(0-infinity) were (435 +/- 47) vs (287 +/- 95) microg x h x L(-1) (in * 1/ * 3 vs * 1/ *1 subjects), and CL/F were (96 +/- 9.3) vs (160 +/- 51) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[h·μg] / [l],435,145411,DB00554,Piroxicam
,16342679,AUC(0-infinity),"AUC(0-infinity) were (435 +/- 47) vs (287 +/- 95) microg x h x L(-1) (in * 1/ * 3 vs * 1/ *1 subjects), and CL/F were (96 +/- 9.3) vs (160 +/- 51) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[h·μg] / [l],287,145412,DB00554,Piroxicam
,16342679,CL/F,"AUC(0-infinity) were (435 +/- 47) vs (287 +/- 95) microg x h x L(-1) (in * 1/ * 3 vs * 1/ *1 subjects), and CL/F were (96 +/- 9.3) vs (160 +/- 51) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[ml] / [min],96,145413,DB00554,Piroxicam
,16342679,CL/F,"AUC(0-infinity) were (435 +/- 47) vs (287 +/- 95) microg x h x L(-1) (in * 1/ * 3 vs * 1/ *1 subjects), and CL/F were (96 +/- 9.3) vs (160 +/- 51) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[ml] / [min],160,145414,DB00554,Piroxicam
,16342679,C(max),"After a single oral dose of 8 mg lornoxicam, C(max) was (1.54 +/- 0.24) mg x L(-1) in CYP2C9 * 1/ * 3 subjects and (1.19 +/- 0.37) mg x L(-1) in * 1/ * 1 subjects.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[mg] / [l],1.54,145415,DB00554,Piroxicam
,16342679,C(max),"After a single oral dose of 8 mg lornoxicam, C(max) was (1.54 +/- 0.24) mg x L(-1) in CYP2C9 * 1/ * 3 subjects and (1.19 +/- 0.37) mg x L(-1) in * 1/ * 1 subjects.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[mg] / [l],1.19,145416,DB00554,Piroxicam
,16342679,AUC(o-infinity,"AUC(o-infinity were (14.9 +/- 2.2) vs (6.92 +/- 1.48) mg x h x L(-1) (in * 1/ *3 vs * 1/ * 1 subjects), and CL/F were (9.1 +/- 1.2) vs (20.1 +/- 4.6) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[h·mg] / [l],14.9,145417,DB00554,Piroxicam
,16342679,AUC(o-infinity,"AUC(o-infinity were (14.9 +/- 2.2) vs (6.92 +/- 1.48) mg x h x L(-1) (in * 1/ *3 vs * 1/ * 1 subjects), and CL/F were (9.1 +/- 1.2) vs (20.1 +/- 4.6) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[h·mg] / [l],6.92,145418,DB00554,Piroxicam
,16342679,CL/F,"AUC(o-infinity were (14.9 +/- 2.2) vs (6.92 +/- 1.48) mg x h x L(-1) (in * 1/ *3 vs * 1/ * 1 subjects), and CL/F were (9.1 +/- 1.2) vs (20.1 +/- 4.6) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[ml] / [min],9.1,145419,DB00554,Piroxicam
,16342679,CL/F,"AUC(o-infinity were (14.9 +/- 2.2) vs (6.92 +/- 1.48) mg x h x L(-1) (in * 1/ *3 vs * 1/ * 1 subjects), and CL/F were (9.1 +/- 1.2) vs (20.1 +/- 4.6) mL x min(-1), respectively.",[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342679/),[ml] / [min],20.1,145420,DB00554,Piroxicam
<,8024649,plasma clearances,"However, based on literature data for 18 non-steroidal anti-inflammatory drugs (NSAIDs) with low plasma clearances (< 60 ml/min), we have shown that most of these low-extraction compounds are non-restrictively eliminated, i.e. their hepatic extraction ratio exceeds their unbound fraction in plasma.",Non-steroidal anti-inflammatory drugs: restrictive or non-restrictive hepatic clearance? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8024649/),[ml] / [min],60,146392,DB00554,Piroxicam
,4065194,elimination half life,The elimination half life of piroxicam for the adults was 57.1 +/- 16.4 h (mean +/- SD; harmonic mean 52.9 h) and for the elderly subjects was 57.8 +/- 22.1 h (harmonic mean 52.1 h).,"Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4065194/),h,57.1,146878,DB00554,Piroxicam
,4065194,elimination half life,The elimination half life of piroxicam for the adults was 57.1 +/- 16.4 h (mean +/- SD; harmonic mean 52.9 h) and for the elderly subjects was 57.8 +/- 22.1 h (harmonic mean 52.1 h).,"Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4065194/),h,52.9,146879,DB00554,Piroxicam
,4065194,elimination half life,The elimination half life of piroxicam for the adults was 57.1 +/- 16.4 h (mean +/- SD; harmonic mean 52.9 h) and for the elderly subjects was 57.8 +/- 22.1 h (harmonic mean 52.1 h).,"Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4065194/),h,57.8,146880,DB00554,Piroxicam
,4065194,elimination half life,The elimination half life of piroxicam for the adults was 57.1 +/- 16.4 h (mean +/- SD; harmonic mean 52.9 h) and for the elderly subjects was 57.8 +/- 22.1 h (harmonic mean 52.1 h).,"Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4065194/),h,52.1,146881,DB00554,Piroxicam
,4065194,AUC0-infinity,Similarly no differences were noted in either the AUC0-infinity after piroxicam (adults 154.1 +/- 52.2 micrograms .,"Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4065194/),μg,154.1,146882,DB00554,Piroxicam
,4065194,apparent oral clearance,"h/ml, elderly 787.9 +/- 613.1 micrograms . h/ml) or the apparent oral clearance of piroxicam (adults 2.39 +/- 0.80 ml/min, elderly 2.51 +/- 0.90 ml/min) and isoxicam (adults 5.84 +/- 2.04 ml/min, elderly 5.59 +/- 2.12 ml/min).","Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4065194/),[ml] / [min],2.39,146883,DB00554,Piroxicam
,4065194,apparent oral clearance,"h/ml, elderly 787.9 +/- 613.1 micrograms . h/ml) or the apparent oral clearance of piroxicam (adults 2.39 +/- 0.80 ml/min, elderly 2.51 +/- 0.90 ml/min) and isoxicam (adults 5.84 +/- 2.04 ml/min, elderly 5.59 +/- 2.12 ml/min).","Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4065194/),[ml] / [min],2.51,146884,DB00554,Piroxicam
,4065194,apparent oral clearance,"h/ml, elderly 787.9 +/- 613.1 micrograms . h/ml) or the apparent oral clearance of piroxicam (adults 2.39 +/- 0.80 ml/min, elderly 2.51 +/- 0.90 ml/min) and isoxicam (adults 5.84 +/- 2.04 ml/min, elderly 5.59 +/- 2.12 ml/min).","Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4065194/),[ml] / [min],5.84,146885,DB00554,Piroxicam
,4065194,apparent oral clearance,"h/ml, elderly 787.9 +/- 613.1 micrograms . h/ml) or the apparent oral clearance of piroxicam (adults 2.39 +/- 0.80 ml/min, elderly 2.51 +/- 0.90 ml/min) and isoxicam (adults 5.84 +/- 2.04 ml/min, elderly 5.59 +/- 2.12 ml/min).","Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4065194/),[ml] / [min],5.59,146886,DB00554,Piroxicam
,29638052,flow rate,The optimized flow rate of 1.0 mL/min provided proper separation of peaks and column clean up within 5 min.,DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),[ml] / [min],1.0,148447,DB00554,Piroxicam
,29638052,C.,The values of C. and area under curve for current study were 1.776 ± 0.003 pg/mL and 179.97 ± 0.0681 (mean ± SEM) pg x h/mL.,DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),[pg] / [ml],1.776,148448,DB00554,Piroxicam
,29638052,area under curve,The values of C. and area under curve for current study were 1.776 ± 0.003 pg/mL and 179.97 ± 0.0681 (mean ± SEM) pg x h/mL.,DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),[h·pg] / [ml],179.97,148449,DB00554,Piroxicam
,29638052,t,"The values of t, and volume of distribution for tenoxicam in current study were 74.103 0.167 h (mean ± SEM) and 11.962 ± 0.0677 L/kg (mean ± SEM), respectively.",DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),h,74.103,148450,DB00554,Piroxicam
,29638052,volume of distribution,"The values of t, and volume of distribution for tenoxicam in current study were 74.103 0.167 h (mean ± SEM) and 11.962 ± 0.0677 L/kg (mean ± SEM), respectively.",DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),h,0.167,148451,DB00554,Piroxicam
,29638052,volume of distribution,"The values of t, and volume of distribution for tenoxicam in current study were 74.103 0.167 h (mean ± SEM) and 11.962 ± 0.0677 L/kg (mean ± SEM), respectively.",DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),[l] / [kg],11.962,148452,DB00554,Piroxicam
,11075311,absorption rate,The absorption rate of PBCD (5/h) was faster than Feldene (1.41/h).,Comparative population pharmacokinetic-pharmacodynamic analysis for piroxicam-beta-cyclodextrin and piroxicam. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11075311/),1/[h],5,149653,DB00554,Piroxicam
,11075311,absorption rate,The absorption rate of PBCD (5/h) was faster than Feldene (1.41/h).,Comparative population pharmacokinetic-pharmacodynamic analysis for piroxicam-beta-cyclodextrin and piroxicam. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11075311/),1/[h],1.41,149654,DB00554,Piroxicam
,11075311,half-life,The estimated half-life of the equilibration between plasma and effect site was about 2.34 hours.,Comparative population pharmacokinetic-pharmacodynamic analysis for piroxicam-beta-cyclodextrin and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11075311/),h,2.34,149655,DB00554,Piroxicam
,10486432,pK(a),Px solubility in water increased markedly with increasing pH from pH 6 as Px is a weak acid and its pK(a) is 5.3.,"Influence of non-ionic surfactants, pH and propylene glycol on percutaneous absorption of piroxicam from cataplasm. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10486432/),,5.3,152155,DB00554,Piroxicam
,17921074,flow rate of mobile phase,"The flow rate of mobile phase was 1.2 ml/min and the retention time of meloxicam and internal standard, piroxicam, was found to be 11.6 and 6.3 min, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),[ml] / [min],1.2,153005,DB00554,Piroxicam
,17921074,retention time,"The flow rate of mobile phase was 1.2 ml/min and the retention time of meloxicam and internal standard, piroxicam, was found to be 11.6 and 6.3 min, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),min,11.6,153006,DB00554,Piroxicam
,17921074,retention time,"The flow rate of mobile phase was 1.2 ml/min and the retention time of meloxicam and internal standard, piroxicam, was found to be 11.6 and 6.3 min, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),min,6.3,153007,DB00554,Piroxicam
,17921074,AUCinf,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),[h·μg] / [ml],42.4,153008,DB00554,Piroxicam
,17921074,Cmax,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),[ng] / [ml],1445.7,153009,DB00554,Piroxicam
,17921074,Cmax,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),h,4.1,153010,DB00554,Piroxicam
,17921074,tmax,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),[ng] / [ml],1445.7,153011,DB00554,Piroxicam
,17921074,tmax,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),h,4.1,153012,DB00554,Piroxicam
,17921074,t1/2,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),h,22.0,153013,DB00554,Piroxicam
,22784220,Peff,"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),[cm] / [s],0.16-44.16 × 10(-4),154149,DB00554,Piroxicam
,22784220,fraction unbound to plasma proteins (fu),"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.01-0.99,154150,DB00554,Piroxicam
,22784220,Saliva/plasma concentrations ratios,"Saliva/plasma concentrations ratios ranged 0.11-13.4, in agreement with drug protein binding and permeability.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.11-13.4,154151,DB00554,Piroxicam
,33913999,Areas under the curve (AUC0-t(,"Areas under the curve (AUC0-t(h*ng/mL)) for CYP2C9*1/*1, *1/*2 and *1/*3 were, respectively, 194.33±70.93, 166 and 303.",Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33913999/),,194.33,158890,DB00554,Piroxicam
,33913999,Areas under the curve (AUC0-t(,"Areas under the curve (AUC0-t(h*ng/mL)) for CYP2C9*1/*1, *1/*2 and *1/*3 were, respectively, 194.33±70.93, 166 and 303.",Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33913999/),,166,158891,DB00554,Piroxicam
,33913999,Areas under the curve (AUC0-t(,"Areas under the curve (AUC0-t(h*ng/mL)) for CYP2C9*1/*1, *1/*2 and *1/*3 were, respectively, 194.33±70.93, 166 and 303.",Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33913999/),,303,158892,DB00554,Piroxicam
,33913999,Maximum concentrations (Cmax,"Maximum concentrations (Cmax(ng/mL)) for these genotypes were respectively 6.46±2.56, 4.3 and 10.2.",Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33913999/),[ng] / [ml],6.46,158893,DB00554,Piroxicam
,33913999,Maximum concentrations (Cmax,"Maximum concentrations (Cmax(ng/mL)) for these genotypes were respectively 6.46±2.56, 4.3 and 10.2.",Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33913999/),[ng] / [ml],4.3,158894,DB00554,Piroxicam
,33913999,Maximum concentrations (Cmax,"Maximum concentrations (Cmax(ng/mL)) for these genotypes were respectively 6.46±2.56, 4.3 and 10.2.",Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33913999/),[ng] / [ml],10.2,158895,DB00554,Piroxicam
,3709612,areas under the plasma concentration-time curve,"The mean areas under the plasma concentration-time curve (138 +/- 53 micrograms/ml X h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam.",Pharmacokinetics of tenoxicam in patients with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709612/),[μg] / [h·ml],138,159033,DB00554,Piroxicam
,4061466,half-life,The results indicate that the mean half-life of isoxicam is approximately 24 hours and is independent of dosage.,Pharmacokinetics of isoxicam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4061466/),h,24,168668,DB00554,Piroxicam
,1887556,elimination half-life,"It had an elimination half-life of 40.2 hours, a volume of distribution of 0.29 +/- 0.02 litres/kg and a body clearance rate of 0.066 litres/hour.",Pharmacokinetics and pharmacodynamics of piroxicam in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1887556/),h,40.2,170160,DB00554,Piroxicam
,1887556,volume of distribution,"It had an elimination half-life of 40.2 hours, a volume of distribution of 0.29 +/- 0.02 litres/kg and a body clearance rate of 0.066 litres/hour.",Pharmacokinetics and pharmacodynamics of piroxicam in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1887556/),[l] / [kg],0.29,170161,DB00554,Piroxicam
,1887556,body clearance rate,"It had an elimination half-life of 40.2 hours, a volume of distribution of 0.29 +/- 0.02 litres/kg and a body clearance rate of 0.066 litres/hour.",Pharmacokinetics and pharmacodynamics of piroxicam in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1887556/),[l] / [h],0.066,170162,DB00554,Piroxicam
,1887556,bioavailable,When administered orally it was 100 per cent bioavailable and maximum plasma concentrations were achieved quickly (3.1 +/- 1.0 hours).,Pharmacokinetics and pharmacodynamics of piroxicam in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1887556/),%,100,170163,DB00554,Piroxicam
,3957490,bioavailability,"This treatment reduced the mean bioavailability of piroxicam by 41.7% (oral) or 48.8% (rectal), relative to the control.",The effect of activated charcoal on the bioavailability of piroxicam in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957490/),%,41.7,171361,DB00554,Piroxicam
,3957490,bioavailability,"This treatment reduced the mean bioavailability of piroxicam by 41.7% (oral) or 48.8% (rectal), relative to the control.",The effect of activated charcoal on the bioavailability of piroxicam in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957490/),%,48.8,171362,DB00554,Piroxicam
,3957490,Half-lives of elimination,Half-lives of elimination were reduced on the average from 40.2 h to 19.6 h after the oral dose and from 40.7 h to 21.6 hours after the rectal dose under the a.c. treatment.,The effect of activated charcoal on the bioavailability of piroxicam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957490/),h,40.2,171363,DB00554,Piroxicam
,3957490,Half-lives of elimination,Half-lives of elimination were reduced on the average from 40.2 h to 19.6 h after the oral dose and from 40.7 h to 21.6 hours after the rectal dose under the a.c. treatment.,The effect of activated charcoal on the bioavailability of piroxicam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957490/),h,19.6,171364,DB00554,Piroxicam
,3957490,Half-lives of elimination,Half-lives of elimination were reduced on the average from 40.2 h to 19.6 h after the oral dose and from 40.7 h to 21.6 hours after the rectal dose under the a.c. treatment.,The effect of activated charcoal on the bioavailability of piroxicam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957490/),h,40.7,171365,DB00554,Piroxicam
,3957490,Half-lives of elimination,Half-lives of elimination were reduced on the average from 40.2 h to 19.6 h after the oral dose and from 40.7 h to 21.6 hours after the rectal dose under the a.c. treatment.,The effect of activated charcoal on the bioavailability of piroxicam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957490/),h,21.6,171366,DB00554,Piroxicam
,6148211,Plasma elimination half-lives,Plasma elimination half-lives were 22-45 hr in man and 49-53 hr in dogs and 20-35 hr in rats and monkeys.,"Metabolic disposition of isoxicam in man, monkey, dog, and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148211/),h,22-45,172536,DB00554,Piroxicam
,6148211,Plasma elimination half-lives,Plasma elimination half-lives were 22-45 hr in man and 49-53 hr in dogs and 20-35 hr in rats and monkeys.,"Metabolic disposition of isoxicam in man, monkey, dog, and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148211/),h,49-53,172537,DB00554,Piroxicam
,6148211,Plasma elimination half-lives,Plasma elimination half-lives were 22-45 hr in man and 49-53 hr in dogs and 20-35 hr in rats and monkeys.,"Metabolic disposition of isoxicam in man, monkey, dog, and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148211/),h,20-35,172538,DB00554,Piroxicam
,3497039,clearance,"Model-independent analysis showed the clearance, elimination half-life and apparent volume of distribution to be independent of dose with mean values of 0.096 L/h, 76 h and 9.2 L respectively.",Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3497039/),[l] / [h],0.096,174943,DB00554,Piroxicam
,3497039,elimination half-life,"Model-independent analysis showed the clearance, elimination half-life and apparent volume of distribution to be independent of dose with mean values of 0.096 L/h, 76 h and 9.2 L respectively.",Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3497039/),h,76,174944,DB00554,Piroxicam
,3497039,apparent volume of distribution,"Model-independent analysis showed the clearance, elimination half-life and apparent volume of distribution to be independent of dose with mean values of 0.096 L/h, 76 h and 9.2 L respectively.",Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3497039/),l,9.2,174945,DB00554,Piroxicam
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,0.53,175748,DB00554,Piroxicam
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,0.28,175749,DB00554,Piroxicam
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,2.76,175750,DB00554,Piroxicam
,9777110,faecal blood loss,"Mean 24 hour faecal blood loss with diclofenac (0.53 mL +/- 0.21) was not significantly different from control (0.28 mL +/- 0.06), whereas it was significantly increased with naproxen (2.76 mL +/- 2.22) and piroxicam (1.16 mL +/- 0.62), p = 0.0013.",NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777110/),ml,1.16,175751,DB00554,Piroxicam
,26760238,flow injection,"Piroxicam and its major metabolite were separated using a LiChroCART 125-4 RP Select-B Sorbent C18 column using a mixture of methanol and 2% phosphoric acid (pH 2.7) (70:30, v/v) for the mobile phase with a flow injection of 1mL/min.",Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),[ml] / [min],1,178860,DB00554,Piroxicam
,26760238,run time,The run time was 4min.,Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),min,4,178861,DB00554,Piroxicam
,26760238,AUC0-72,"The pharmacokinetic parameters of piroxicam in plasma samples were as follows: AUC0-72 (64819hng/mL), predicted clearance (0.2L/h), distribution volume (14.8L), elimination half-life (50.7h) and saliva/plasma concentration ratio (0.003).",Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),[hng] / [ml],64819,178862,DB00554,Piroxicam
,26760238,clearance,"The pharmacokinetic parameters of piroxicam in plasma samples were as follows: AUC0-72 (64819hng/mL), predicted clearance (0.2L/h), distribution volume (14.8L), elimination half-life (50.7h) and saliva/plasma concentration ratio (0.003).",Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),[l] / [h],0.2,178863,DB00554,Piroxicam
,26760238,distribution volume,"The pharmacokinetic parameters of piroxicam in plasma samples were as follows: AUC0-72 (64819hng/mL), predicted clearance (0.2L/h), distribution volume (14.8L), elimination half-life (50.7h) and saliva/plasma concentration ratio (0.003).",Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),l,14.8,178864,DB00554,Piroxicam
,26760238,elimination half-life,"The pharmacokinetic parameters of piroxicam in plasma samples were as follows: AUC0-72 (64819hng/mL), predicted clearance (0.2L/h), distribution volume (14.8L), elimination half-life (50.7h) and saliva/plasma concentration ratio (0.003).",Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),h,50.7,178865,DB00554,Piroxicam
,26760238,saliva/plasma concentration ratio,"The pharmacokinetic parameters of piroxicam in plasma samples were as follows: AUC0-72 (64819hng/mL), predicted clearance (0.2L/h), distribution volume (14.8L), elimination half-life (50.7h) and saliva/plasma concentration ratio (0.003).",Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),,0.003,178866,DB00554,Piroxicam
,26760238,maximum concentration,"The estimation of all pharmacokinetic parameters for 5'-hydroxypiroxicam would require collections beyond 72h; however, it was possible to quantify the mean maximum concentration (133ng/mL), time to peak concentration (53.6h), mean AUC0-72 (6213hng/mL), predicted clearance (110.3L/h) and saliva/plasma concentration ratio (0.04).",Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),[ng] / [ml],133,178867,DB00554,Piroxicam
,26760238,time to peak concentration,"The estimation of all pharmacokinetic parameters for 5'-hydroxypiroxicam would require collections beyond 72h; however, it was possible to quantify the mean maximum concentration (133ng/mL), time to peak concentration (53.6h), mean AUC0-72 (6213hng/mL), predicted clearance (110.3L/h) and saliva/plasma concentration ratio (0.04).",Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),h,53.6,178868,DB00554,Piroxicam
,26760238,AUC0-72,"The estimation of all pharmacokinetic parameters for 5'-hydroxypiroxicam would require collections beyond 72h; however, it was possible to quantify the mean maximum concentration (133ng/mL), time to peak concentration (53.6h), mean AUC0-72 (6213hng/mL), predicted clearance (110.3L/h) and saliva/plasma concentration ratio (0.04).",Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),[hng] / [ml],6213,178869,DB00554,Piroxicam
,26760238,clearance,"The estimation of all pharmacokinetic parameters for 5'-hydroxypiroxicam would require collections beyond 72h; however, it was possible to quantify the mean maximum concentration (133ng/mL), time to peak concentration (53.6h), mean AUC0-72 (6213hng/mL), predicted clearance (110.3L/h) and saliva/plasma concentration ratio (0.04).",Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),[l] / [h],110.3,178870,DB00554,Piroxicam
,26760238,saliva/plasma concentration ratio,"The estimation of all pharmacokinetic parameters for 5'-hydroxypiroxicam would require collections beyond 72h; however, it was possible to quantify the mean maximum concentration (133ng/mL), time to peak concentration (53.6h), mean AUC0-72 (6213hng/mL), predicted clearance (110.3L/h) and saliva/plasma concentration ratio (0.04).",Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26760238/),,0.04,178871,DB00554,Piroxicam
,3620273,lambda 1,"Mean disposition parameters were: t1/2, lambda 1 = 3.3 min t1/2, lambda z = 28 h, Vc = 5.61, Vdarea = 12.71, CL = 5.1 ml min-1.","Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620273/),[min·t1] / [2],3.3,179215,DB00554,Piroxicam
,3620273,lambda z,"Mean disposition parameters were: t1/2, lambda 1 = 3.3 min t1/2, lambda z = 28 h, Vc = 5.61, Vdarea = 12.71, CL = 5.1 ml min-1.","Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620273/),h,28,179216,DB00554,Piroxicam
,3620273,Vc,"Mean disposition parameters were: t1/2, lambda 1 = 3.3 min t1/2, lambda z = 28 h, Vc = 5.61, Vdarea = 12.71, CL = 5.1 ml min-1.","Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620273/),,5.61,179217,DB00554,Piroxicam
,3620273,Vdarea,"Mean disposition parameters were: t1/2, lambda 1 = 3.3 min t1/2, lambda z = 28 h, Vc = 5.61, Vdarea = 12.71, CL = 5.1 ml min-1.","Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620273/),,12.71,179218,DB00554,Piroxicam
,3620273,CL,"Mean disposition parameters were: t1/2, lambda 1 = 3.3 min t1/2, lambda z = 28 h, Vc = 5.61, Vdarea = 12.71, CL = 5.1 ml min-1.","Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620273/),[ml] / [min],5.1,179219,DB00554,Piroxicam
,3620273,Maximum plasma concentrations,Maximum plasma concentrations of 11.7 micrograms ml-1 were reached after an average of 3 h.,"Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620273/),[μg] / [ml],11.7,179220,DB00554,Piroxicam
,3620273,peak concentrations,Mean peak concentrations of 12.3 micrograms ml-1 were obtained within 10 h.,"Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620273/),[μg] / [ml],12.3,179221,DB00554,Piroxicam
,512843,half-life of drug,"The half-life of drug in plasma in the fasting subjects (37.5 +/- 2.4 hr) was similar in both the fasting state and after food, suggesting that once-daily dosing may be appropriate for maintaining therapeutic plasma levels.","Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512843/),h,37.5,181142,DB00554,Piroxicam
,512843,volume of distribution divided by availability,"Mean pharmacokinetic parameters for both studies in the fasting state and after meals are volume of distribution divided by availability, 0.140 or 0.136 liter/kg; total plasma clearance divided by availability, 2.68 or 3.12 ml/hr/kg.","Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512843/),[l] / [kg],0.140,181143,DB00554,Piroxicam
,512843,volume of distribution divided by availability,"Mean pharmacokinetic parameters for both studies in the fasting state and after meals are volume of distribution divided by availability, 0.140 or 0.136 liter/kg; total plasma clearance divided by availability, 2.68 or 3.12 ml/hr/kg.","Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512843/),[l] / [kg],0.136,181144,DB00554,Piroxicam
,512843,total plasma clearance divided by availability,"Mean pharmacokinetic parameters for both studies in the fasting state and after meals are volume of distribution divided by availability, 0.140 or 0.136 liter/kg; total plasma clearance divided by availability, 2.68 or 3.12 ml/hr/kg.","Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512843/),[ml] / [h·kg],2.68,181145,DB00554,Piroxicam
,512843,total plasma clearance divided by availability,"Mean pharmacokinetic parameters for both studies in the fasting state and after meals are volume of distribution divided by availability, 0.140 or 0.136 liter/kg; total plasma clearance divided by availability, 2.68 or 3.12 ml/hr/kg.","Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512843/),[ml] / [h·kg],3.12,181146,DB00554,Piroxicam
,512843,Renal clearance,"Renal clearance of the drug (0.28 +/- 0.10 ml/hr/kg) was 10.4% or less of plasma clearance, suggesting that piroxicam is extensively metabolized.","Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512843/),[ml] / [h·kg],0.28,181147,DB00554,Piroxicam
,3723402,adsorption capacity,The Langmuir binding isotherms determined in buffer solutions at pH 7.5 indicated a much greater adsorption capacity of cholestyramine (1.63 g of drug per g of resin) than of charcoal (0.18 g/g of adsorbent) for the acidic drug with a pKa of 5.3.,Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),g,1.63,188465,DB00554,Piroxicam
,3723402,adsorption capacity,The Langmuir binding isotherms determined in buffer solutions at pH 7.5 indicated a much greater adsorption capacity of cholestyramine (1.63 g of drug per g of resin) than of charcoal (0.18 g/g of adsorbent) for the acidic drug with a pKa of 5.3.,Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),[g] / [g],0.18,188466,DB00554,Piroxicam
,3723402,pKa,The Langmuir binding isotherms determined in buffer solutions at pH 7.5 indicated a much greater adsorption capacity of cholestyramine (1.63 g of drug per g of resin) than of charcoal (0.18 g/g of adsorbent) for the acidic drug with a pKa of 5.3.,Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),,5.3,188467,DB00554,Piroxicam
,3723402,total body clearance,"Due to an increased total body clearance (0.65 vs. 0.13 liters/hr), the elimination half-life was reduced from a median base-line value of 31 to 5.4 hr and the mean residence time of drug in the body was decreased from 41 to 7.9 hr.",Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),[l] / [h],0.65,188468,DB00554,Piroxicam
,3723402,total body clearance,"Due to an increased total body clearance (0.65 vs. 0.13 liters/hr), the elimination half-life was reduced from a median base-line value of 31 to 5.4 hr and the mean residence time of drug in the body was decreased from 41 to 7.9 hr.",Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),[l] / [h],0.13,188469,DB00554,Piroxicam
,3723402,elimination half-life,"Due to an increased total body clearance (0.65 vs. 0.13 liters/hr), the elimination half-life was reduced from a median base-line value of 31 to 5.4 hr and the mean residence time of drug in the body was decreased from 41 to 7.9 hr.",Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),h,31 to 5.4,188470,DB00554,Piroxicam
,3723402,mean residence time of drug,"Due to an increased total body clearance (0.65 vs. 0.13 liters/hr), the elimination half-life was reduced from a median base-line value of 31 to 5.4 hr and the mean residence time of drug in the body was decreased from 41 to 7.9 hr.",Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),h,41,188471,DB00554,Piroxicam
,15606435,t(1/2),"Of the 18 subjects, one subject was found to be a very poor metabolizer of lornoxicam with a long t(1/2) of 106 h, a low CL/F of 0.71 ml min(-1), and a high AUC(0-infinity) of 187.6 microg ml(-1) h.",Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606435/),h,106,189140,DB00554,Piroxicam
,15606435,CL/F,"Of the 18 subjects, one subject was found to be a very poor metabolizer of lornoxicam with a long t(1/2) of 106 h, a low CL/F of 0.71 ml min(-1), and a high AUC(0-infinity) of 187.6 microg ml(-1) h.",Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606435/),[ml] / [min],0.71,189141,DB00554,Piroxicam
,15606435,AUC(0-infinity),"Of the 18 subjects, one subject was found to be a very poor metabolizer of lornoxicam with a long t(1/2) of 106 h, a low CL/F of 0.71 ml min(-1), and a high AUC(0-infinity) of 187.6 microg ml(-1) h.",Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606435/),[h·μg] / [ml],187.6,189142,DB00554,Piroxicam
,15606435,AUC(0-infinity),"Mean AUC(0-infinity) values (95% confidence intervals) of lornoxicam were 9.25 (6.55, 11.95) vs. 4.75 (3.55, 5.95) microg ml(-1) h in *1 heterozygotes vs.*1 homozygotes, and mean CL/F values were 14.8 (10.2, 19.4) vs. 32.9 (24.5, 41.3) ml min(-1), respectively (P < 0.05 for both AUC and CL/F).",Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606435/),[h·μg] / [ml],9.25,189143,DB00554,Piroxicam
,15606435,AUC(0-infinity),"Mean AUC(0-infinity) values (95% confidence intervals) of lornoxicam were 9.25 (6.55, 11.95) vs. 4.75 (3.55, 5.95) microg ml(-1) h in *1 heterozygotes vs.*1 homozygotes, and mean CL/F values were 14.8 (10.2, 19.4) vs. 32.9 (24.5, 41.3) ml min(-1), respectively (P < 0.05 for both AUC and CL/F).",Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606435/),[h·μg] / [ml],4.75,189144,DB00554,Piroxicam
,15606435,CL/F,"Mean AUC(0-infinity) values (95% confidence intervals) of lornoxicam were 9.25 (6.55, 11.95) vs. 4.75 (3.55, 5.95) microg ml(-1) h in *1 heterozygotes vs.*1 homozygotes, and mean CL/F values were 14.8 (10.2, 19.4) vs. 32.9 (24.5, 41.3) ml min(-1), respectively (P < 0.05 for both AUC and CL/F).",Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606435/),[ml] / [min],14.8,189145,DB00554,Piroxicam
,15606435,CL/F,"Mean AUC(0-infinity) values (95% confidence intervals) of lornoxicam were 9.25 (6.55, 11.95) vs. 4.75 (3.55, 5.95) microg ml(-1) h in *1 heterozygotes vs.*1 homozygotes, and mean CL/F values were 14.8 (10.2, 19.4) vs. 32.9 (24.5, 41.3) ml min(-1), respectively (P < 0.05 for both AUC and CL/F).",Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606435/),[ml] / [min],32.9,189146,DB00554,Piroxicam
,11397584,area under the plasma concentration curve,Following intravenous administration the area under the plasma concentration curve was 2452.17+/-86.49 ng h/ml as compared to 1357.69+/-102.36 ng h/ml following intranasal dosing.,Intranasal delivery of tenoxicam in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397584/),[h·ng] / [ml],2452.17,190331,DB00554,Piroxicam
,11397584,area under the plasma concentration curve,Following intravenous administration the area under the plasma concentration curve was 2452.17+/-86.49 ng h/ml as compared to 1357.69+/-102.36 ng h/ml following intranasal dosing.,Intranasal delivery of tenoxicam in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397584/),[h·ng] / [ml],1357.69,190332,DB00554,Piroxicam
,11397584,relative bioavailability,This corresponds to a relative bioavailability of 55.36%.,Intranasal delivery of tenoxicam in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397584/),%,55.36,190333,DB00554,Piroxicam
,8218966,F(abs),"The extent of absorption of intramuscularly administered tenoxicam was complete (mean +/- CV per cent: F(abs) 0.99 +/- 20 per cent) with no difference between the two extravascular administrations (F(rel) 0.95 +/- 10 per cent, intramuscular vs oral).",Bioavailability of intramuscularly administered tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),%,0.99,193708,DB00554,Piroxicam
,8218966,F(rel),"The extent of absorption of intramuscularly administered tenoxicam was complete (mean +/- CV per cent: F(abs) 0.99 +/- 20 per cent) with no difference between the two extravascular administrations (F(rel) 0.95 +/- 10 per cent, intramuscular vs oral).",Bioavailability of intramuscularly administered tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),%,0.95,193709,DB00554,Piroxicam
,8218966,Tmax,After intramuscular administration tenoxicam was more rapidly absorbed compared to the oral dose (Tmax 0.71 h +/- 80 per cent vs 1.4 h +/- 62 per cent; p > 0.05).,Bioavailability of intramuscularly administered tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),h,0.71,193710,DB00554,Piroxicam
,8218966,Tmax,After intramuscular administration tenoxicam was more rapidly absorbed compared to the oral dose (Tmax 0.71 h +/- 80 per cent vs 1.4 h +/- 62 per cent; p > 0.05).,Bioavailability of intramuscularly administered tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),h,1.4,193711,DB00554,Piroxicam
,8218966,Peak concentrations,Peak concentrations after oral and intramuscular administration (Cmax 2.5 mg l-1 +/- 19 per cent vs 2.7 mg l-1 +/- 14 per cent; p < 0.05) were very similar.,Bioavailability of intramuscularly administered tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),[mg] / [l],2.5,193712,DB00554,Piroxicam
,8218966,Cmax,Peak concentrations after oral and intramuscular administration (Cmax 2.5 mg l-1 +/- 19 per cent vs 2.7 mg l-1 +/- 14 per cent; p < 0.05) were very similar.,Bioavailability of intramuscularly administered tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),[mg] / [l],2.5,193713,DB00554,Piroxicam
,8218966,Cmax,Peak concentrations after oral and intramuscular administration (Cmax 2.5 mg l-1 +/- 19 per cent vs 2.7 mg l-1 +/- 14 per cent; p < 0.05) were very similar.,Bioavailability of intramuscularly administered tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),[mg] / [l],2.7,193714,DB00554,Piroxicam
,17708397,overall survival time,Both the median overall survival time and the median disease-free interval in dogs treated with LDC were 178 days.,Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17708397/),d,178,195038,DB00554,Piroxicam
,17708397,overall survival time,"By comparison, the overall survival time and disease-free interval in dogs treated with DOX were 133 and 126 days, respectively.",Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17708397/),d,133,195039,DB00554,Piroxicam
,17708397,disease-free interval,"By comparison, the overall survival time and disease-free interval in dogs treated with DOX were 133 and 126 days, respectively.",Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17708397/),d,126,195040,DB00554,Piroxicam
,11204935,peak concentration,"The peak concentration was higher in plasma (2.51+/-0.25 microg/ml) than in SF (1.31+/-0.76 microg/ml), but the elimination half-life was much longer in SF (90.7 h) than in plasma (32.5 h).",Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204935/),[μg] / [ml],2.51,196266,DB00554,Piroxicam
,11204935,peak concentration,"The peak concentration was higher in plasma (2.51+/-0.25 microg/ml) than in SF (1.31+/-0.76 microg/ml), but the elimination half-life was much longer in SF (90.7 h) than in plasma (32.5 h).",Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204935/),[μg] / [ml],1.31,196267,DB00554,Piroxicam
,11204935,elimination half-life,"The peak concentration was higher in plasma (2.51+/-0.25 microg/ml) than in SF (1.31+/-0.76 microg/ml), but the elimination half-life was much longer in SF (90.7 h) than in plasma (32.5 h).",Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204935/),h,90.7,196268,DB00554,Piroxicam
,11204935,elimination half-life,"The peak concentration was higher in plasma (2.51+/-0.25 microg/ml) than in SF (1.31+/-0.76 microg/ml), but the elimination half-life was much longer in SF (90.7 h) than in plasma (32.5 h).",Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204935/),h,32.5,196269,DB00554,Piroxicam
,11204935,area under the concentration-time curve ratio,The SF/plasma area under the concentration-time curve ratio (evaluating the quantity of NSAID transferred from the blood to the joint) was equal to 0.39.,Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204935/),,0.39,196270,DB00554,Piroxicam
,9646006,plasma half-life,"Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours).",Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646006/),h,3 to 5,196622,DB00554,Piroxicam
,9646006,half-life,Glucoroconjugated metabolites are excreted in urine and faeces with a half-life of about 11 hours.,Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646006/),h,11,196623,DB00554,Piroxicam
,2328308,terminal half-life,A prolonged terminal half-life averaging 13.3 h in male rats and 40.8 h in female rats was observed.,Effects of dose and sex on the pharmacokinetics of piroxicam in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328308/),h,13.3,196641,DB00554,Piroxicam
,2328308,terminal half-life,A prolonged terminal half-life averaging 13.3 h in male rats and 40.8 h in female rats was observed.,Effects of dose and sex on the pharmacokinetics of piroxicam in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328308/),h,40.8,196642,DB00554,Piroxicam
,2328308,total clearance,"The sex of the rat, however, had a marked effect on piroxicam pharmacokinetics, with mean total clearance differing three-fold from 0.0184 l h-1 kg-1 in male rats to 0.00622 l h-1 kg-1 in female rats.",Effects of dose and sex on the pharmacokinetics of piroxicam in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328308/),[l] / [h·kg],0.0184,196643,DB00554,Piroxicam
,2328308,total clearance,"The sex of the rat, however, had a marked effect on piroxicam pharmacokinetics, with mean total clearance differing three-fold from 0.0184 l h-1 kg-1 in male rats to 0.00622 l h-1 kg-1 in female rats.",Effects of dose and sex on the pharmacokinetics of piroxicam in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328308/),[l] / [h·kg],0.00622,196644,DB00554,Piroxicam
,2328308,clearance,"Free piroxicam clearance differed approximately two-fold with mean values of 0.764 l h-1 kg-1 and 0.418 l h-1 kg-1 in male and female rats, respectively.",Effects of dose and sex on the pharmacokinetics of piroxicam in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328308/),[l] / [h·kg],0.764,196645,DB00554,Piroxicam
,2328308,clearance,"Free piroxicam clearance differed approximately two-fold with mean values of 0.764 l h-1 kg-1 and 0.418 l h-1 kg-1 in male and female rats, respectively.",Effects of dose and sex on the pharmacokinetics of piroxicam in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328308/),[l] / [h·kg],0.418,196646,DB00554,Piroxicam
,3402526,half-life,Piroxicam was eliminated from plasma with a half-life of 41.7 h and 43.2 h from synovial fluid as calculated from measured and interpolated data from all patients.,Transsynovial kinetics of piroxicam in patients with rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402526/),h,41.7,198794,DB00554,Piroxicam
,3402526,half-life,Piroxicam was eliminated from plasma with a half-life of 41.7 h and 43.2 h from synovial fluid as calculated from measured and interpolated data from all patients.,Transsynovial kinetics of piroxicam in patients with rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402526/),h,43.2,198795,DB00554,Piroxicam
,7639082,Cmax(s),After transdermal administration of 0.25 mg of piroxicam gels Cmax(s) = 8.06 micrograms.,[Comparison of concentration of piroxicam in blood and local site after two routes of administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639082/),μg,8.06,199145,DB00554,Piroxicam
,7639082,AUC(s)0-24(s),ml-1 and AUC(s)0-24(s) = 58.36 micrograms.,[Comparison of concentration of piroxicam in blood and local site after two routes of administration]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639082/),μg,58.36,199146,DB00554,Piroxicam
,7639082,Cmax(s),10 g-1 body weight of piroxicam suspensions Cmax(s) was 36.82 micrograms.,[Comparison of concentration of piroxicam in blood and local site after two routes of administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639082/),μg,36.82,199147,DB00554,Piroxicam
,7639082,AUC(s)0-24,ml-1 and AUC(s)0-24 was 155.59 micrograms.h.ml-1.,[Comparison of concentration of piroxicam in blood and local site after two routes of administration]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639082/),[h·μg] / [ml],155.59,199148,DB00554,Piroxicam
,7639082,C1/Cs ratio,The C1/Cs ratio (0.01) through oral route was far lower than the C1/Cs ratio (0.13) through transdermal route.,[Comparison of concentration of piroxicam in blood and local site after two routes of administration]. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639082/),,0.01,199149,DB00554,Piroxicam
,7639082,C1/Cs ratio,The C1/Cs ratio (0.01) through oral route was far lower than the C1/Cs ratio (0.13) through transdermal route.,[Comparison of concentration of piroxicam in blood and local site after two routes of administration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639082/),,0.13,199150,DB00554,Piroxicam
,7639082,area under local concentration-time curve,The area under local concentration-time curve (15.85 micrograms.h.ml-1) calculated from transdermal administration was much higher than that from oral administration (1.93 micrograms.h.ml-1).,[Comparison of concentration of piroxicam in blood and local site after two routes of administration]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639082/),[h·μg] / [ml],15.85,199151,DB00554,Piroxicam
,7639082,area under local concentration-time curve,The area under local concentration-time curve (15.85 micrograms.h.ml-1) calculated from transdermal administration was much higher than that from oral administration (1.93 micrograms.h.ml-1).,[Comparison of concentration of piroxicam in blood and local site after two routes of administration]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639082/),[h·μg] / [ml],1.93,199152,DB00554,Piroxicam
,3879830,half-life,"However, the mean half-life for synovial fluid (45 hours) was not significantly different from that for plasma (42 hours).",A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879830/),h,45,200159,DB00554,Piroxicam
,3879830,half-life,"However, the mean half-life for synovial fluid (45 hours) was not significantly different from that for plasma (42 hours).",A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879830/),h,42,200160,DB00554,Piroxicam
,19833177,C(max),PX-patch produced a C(max) at 8 h.,A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19833177/),h,8,203030,DB00554,Piroxicam
,3499163,time taken to reach peak,5 Food lengthened the time taken to reach peak tenoxicam concentrations (5.82 +/- 4.6 vs 1.84 +/- 1.0 h in the fasting state; P less than 0.02) and marginally reduced the peak concentrations achieved.,Effect of food and various antacids on the absorption of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499163/),h,5.82,203346,DB00554,Piroxicam
,3499163,time taken to reach peak,5 Food lengthened the time taken to reach peak tenoxicam concentrations (5.82 +/- 4.6 vs 1.84 +/- 1.0 h in the fasting state; P less than 0.02) and marginally reduced the peak concentrations achieved.,Effect of food and various antacids on the absorption of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499163/),h,1.84,203347,DB00554,Piroxicam
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],6.71,203929,DB00554,Piroxicam
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],3.24,203930,DB00554,Piroxicam
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],8.74,203931,DB00554,Piroxicam
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],46.05,203932,DB00554,Piroxicam
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],6.32,203933,DB00554,Piroxicam
not exceed,9167225,overall recovery,The overall recovery of the investigated compounds in lymph did not exceed 5% of the doses given.,Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),%,5,203934,DB00554,Piroxicam
,1487550,maximum peak plasma concentration (Cmax),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),[μg] / [ml],1.53,207156,DB00554,Piroxicam
,1487550,time to peak concentration (Tmax),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),h,7.5,207157,DB00554,Piroxicam
,1487550,t1/2a,"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),h,1.38,207158,DB00554,Piroxicam
,1487550,t1/2el,"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),h,53.3,207159,DB00554,Piroxicam
,1487550,Cl/F,"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),[ml] / [min],2.98,207160,DB00554,Piroxicam
,1487550,volume of distribution (Vd/F),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),l,13.2,207161,DB00554,Piroxicam
,1487550,area under the curve (AUC),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),[μg] / [h·ml],117.6,207162,DB00554,Piroxicam
,10027661,area under the concentration-time curve (AUC),Lornoxicam co-administration resulted in a statistically significant increase of the area under the concentration-time curve (AUC) of the more potent (S)-isomer of phenprocoumon from a median value of 100 (range 68-146) mg x h x 1(-1) to 124 (92-239) mg x h x 1(-1).,Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027661/),h·mg,100,208551,DB00554,Piroxicam
,10027661,area under the concentration-time curve (AUC),Lornoxicam co-administration resulted in a statistically significant increase of the area under the concentration-time curve (AUC) of the more potent (S)-isomer of phenprocoumon from a median value of 100 (range 68-146) mg x h x 1(-1) to 124 (92-239) mg x h x 1(-1).,Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027661/),h·mg,124,208552,DB00554,Piroxicam
,10027661,AUC,"For the (R)-isomer, the AUC increase from 96 (70-142) mg x h x 1(-1) in the absence to 108 (75-155) mg x h x 1(-1) in the presence of lornoxicam was not statistically significant.",Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027661/),h·mg,96,208553,DB00554,Piroxicam
,10027661,AUC,"For the (R)-isomer, the AUC increase from 96 (70-142) mg x h x 1(-1) in the absence to 108 (75-155) mg x h x 1(-1) in the presence of lornoxicam was not statistically significant.",Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027661/),h·mg,108,208554,DB00554,Piroxicam
,3260866,half-lives,The average values of half-lives were reduced (tenoxicam: 31.9 h vs 67.4 h; piroxicam: 28.1 h vs 46.8 h) due to increases in clearance.,The influence of cholestyramine on the elimination of tenoxicam and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260866/),h,31.9,208746,DB00554,Piroxicam
,3260866,half-lives,The average values of half-lives were reduced (tenoxicam: 31.9 h vs 67.4 h; piroxicam: 28.1 h vs 46.8 h) due to increases in clearance.,The influence of cholestyramine on the elimination of tenoxicam and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260866/),h,67.4,208747,DB00554,Piroxicam
,3260866,half-lives,The average values of half-lives were reduced (tenoxicam: 31.9 h vs 67.4 h; piroxicam: 28.1 h vs 46.8 h) due to increases in clearance.,The influence of cholestyramine on the elimination of tenoxicam and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260866/),h,28.1,208748,DB00554,Piroxicam
,3260866,half-lives,The average values of half-lives were reduced (tenoxicam: 31.9 h vs 67.4 h; piroxicam: 28.1 h vs 46.8 h) due to increases in clearance.,The influence of cholestyramine on the elimination of tenoxicam and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260866/),h,46.8,208749,DB00554,Piroxicam
,27583581,relative bioavailability,"The relative bioavailability of S-sSNEDDS (F12) relative to PP or CD was about 151.01 and 98.96%, respectively.",Nanoemulsifying drug delivery system to improve the bioavailability of piroxicam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27583581/),%,151.01,209110,DB00554,Piroxicam
,27583581,relative bioavailability,"The relative bioavailability of S-sSNEDDS (F12) relative to PP or CD was about 151.01 and 98.96%, respectively.",Nanoemulsifying drug delivery system to improve the bioavailability of piroxicam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27583581/),%,98.96,209111,DB00554,Piroxicam
,3255915,elimination half-life,"Chlortenoxicam was found to have a relatively short mean elimination half-life of about 4 hours, with considerable inter-subject variability, but there was no significant difference between young and elderly subjects.",Chlortenoxicam pharmacokinetics in young and elderly human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3255915/),h,4,209131,DB00554,Piroxicam
,3490574,distribution volume,Piroxicam is highly bound (approximately 99%) to plasma proteins and has a small distribution volume (approximately 10 l).,Clinical pharmacokinetics of piroxicam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3490574/),l,10,209668,DB00554,Piroxicam
,3490574,elimination half-life,Piroxicam has a long elimination half-life of about 50 h.,Clinical pharmacokinetics of piroxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3490574/),h,50,209669,DB00554,Piroxicam
,1982764,maximum plasma concentration (Cmax),The mean maximum plasma concentration (Cmax) was 467 ng.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),ng,467,212417,DB00554,Piroxicam
,1982764,area under the plasma concentration vs time curve (AUC),ml-1 in the presence of piroxicam: mean area under the plasma concentration vs time curve (AUC) was 2460 h.ng ml-1 and 2551 h.ng ml-1 respectively; and the mean terminal half-life (t 1/2) was 3.6 h and 3.8 h respectively.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),[h·ng] / [ml],2460,212418,DB00554,Piroxicam
,1982764,area under the plasma concentration vs time curve (AUC),ml-1 in the presence of piroxicam: mean area under the plasma concentration vs time curve (AUC) was 2460 h.ng ml-1 and 2551 h.ng ml-1 respectively; and the mean terminal half-life (t 1/2) was 3.6 h and 3.8 h respectively.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),[h·ng] / [ml],2551,212419,DB00554,Piroxicam
,1982764,terminal half-life (t 1/2),ml-1 in the presence of piroxicam: mean area under the plasma concentration vs time curve (AUC) was 2460 h.ng ml-1 and 2551 h.ng ml-1 respectively; and the mean terminal half-life (t 1/2) was 3.6 h and 3.8 h respectively.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),h,3.6,212420,DB00554,Piroxicam
,1982764,terminal half-life (t 1/2),ml-1 in the presence of piroxicam: mean area under the plasma concentration vs time curve (AUC) was 2460 h.ng ml-1 and 2551 h.ng ml-1 respectively; and the mean terminal half-life (t 1/2) was 3.6 h and 3.8 h respectively.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),h,3.8,212421,DB00554,Piroxicam
,1982764,Cmax,The mean Cmax was 2.1 micrograms.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),μg,2.1,212422,DB00554,Piroxicam
,1982764,AUC,"ml-1 in the presence of ranitidine respectively; mean AUC was 133 h.microgram ml-1 and 137 h.microgram ml-1 respectively, and the mean t 1/2 was 53.6 h and 54.5 h respectively.",A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),[h·μg] / [ml],133,212423,DB00554,Piroxicam
,1982764,AUC,"ml-1 in the presence of ranitidine respectively; mean AUC was 133 h.microgram ml-1 and 137 h.microgram ml-1 respectively, and the mean t 1/2 was 53.6 h and 54.5 h respectively.",A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),[h·μg] / [ml],137,212424,DB00554,Piroxicam
,1982764,t 1/2,"ml-1 in the presence of ranitidine respectively; mean AUC was 133 h.microgram ml-1 and 137 h.microgram ml-1 respectively, and the mean t 1/2 was 53.6 h and 54.5 h respectively.",A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),h,53.6,212425,DB00554,Piroxicam
,1982764,t 1/2,"ml-1 in the presence of ranitidine respectively; mean AUC was 133 h.microgram ml-1 and 137 h.microgram ml-1 respectively, and the mean t 1/2 was 53.6 h and 54.5 h respectively.",A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),h,54.5,212426,DB00554,Piroxicam
,11881981,plasma elimination half-life,A positive correlation was found between an increase in the free fraction (% F) of tenoxicam in plasma and a decrease in the plasma elimination half-life in the low creatinine clearance group (40-20 ml/min.) both after the single-dose and at steady-state.,"Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881981/),[ml] / [min],40-20,213054,DB00554,Piroxicam
,10640513,K(i),Lornoxicam 5'-hydroxylation was competitively inhibited in vitro by both phenprocoumon (K(i) = 1.2 +/- 0.4 microM) and acenocoumarol (K(i) = 5.5 +/- 3.5 microM).,Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640513/),μM,1.2,214118,DB00554,Piroxicam
,10640513,K(i),Lornoxicam 5'-hydroxylation was competitively inhibited in vitro by both phenprocoumon (K(i) = 1.2 +/- 0.4 microM) and acenocoumarol (K(i) = 5.5 +/- 3.5 microM).,Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640513/),μM,5.5,214119,DB00554,Piroxicam
,2788089,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) after the first dose was 2.76 +/- 0.48 micrograms/ml (mean +/- s.d.) and the time to reach Cmax (Tmax) was 5.0 +/- 3.0 h.,Plasma tenoxicam concentrations after single and multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[μg] / [ml],2.76,214584,DB00554,Piroxicam
,2788089,time to reach Cmax (Tmax),Maximum plasma concentration (Cmax) after the first dose was 2.76 +/- 0.48 micrograms/ml (mean +/- s.d.) and the time to reach Cmax (Tmax) was 5.0 +/- 3.0 h.,Plasma tenoxicam concentrations after single and multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),h,5.0,214585,DB00554,Piroxicam
,2788089,area under the plasma concentration-time curve (AUC0-infinity),The area under the plasma concentration-time curve (AUC0-infinity) after a single administration of tenoxicam was 242.5 +/- 73.5 micrograms x h/ml.,Plasma tenoxicam concentrations after single and multiple oral doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[h·μg] / [ml],242.5,214586,DB00554,Piroxicam
,2788089,elimination half-life (t1/2),The elimination half-life (t1/2) was 66.3 +/- 15.8 h and the plasma concentration at 24 hours after dosing (Cmin) was 1.84 +/- 0.33 micrograms/ml.,Plasma tenoxicam concentrations after single and multiple oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),h,66.3,214587,DB00554,Piroxicam
,2788089,plasma concentration at 24 hours after dosing (Cmin),The elimination half-life (t1/2) was 66.3 +/- 15.8 h and the plasma concentration at 24 hours after dosing (Cmin) was 1.84 +/- 0.33 micrograms/ml.,Plasma tenoxicam concentrations after single and multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[μg] / [ml],1.84,214588,DB00554,Piroxicam
,2788089,Cmax,"At steady-state, Cmax averaged 13.63 +/- 3.33 micrograms/ml and Tmax remained 5.0 +/- 3.0 hours.",Plasma tenoxicam concentrations after single and multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[μg] / [ml],13.63,214589,DB00554,Piroxicam
,2788089,Tmax,"At steady-state, Cmax averaged 13.63 +/- 3.33 micrograms/ml and Tmax remained 5.0 +/- 3.0 hours.",Plasma tenoxicam concentrations after single and multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),h,5.0,214590,DB00554,Piroxicam
,2788089,AUC within a dosing interval at steady-state,"AUC within a dosing interval at steady-state was 262.2 +/- 67.0 micrograms x h/ml, Cminss was 9.67 +/- 3.25 micrograms/ml, and t1/2 averaged 74.2 +/- 13.3 h.",Plasma tenoxicam concentrations after single and multiple oral doses. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[h·μg] / [ml],262.2,214591,DB00554,Piroxicam
,2788089,Cminss,"AUC within a dosing interval at steady-state was 262.2 +/- 67.0 micrograms x h/ml, Cminss was 9.67 +/- 3.25 micrograms/ml, and t1/2 averaged 74.2 +/- 13.3 h.",Plasma tenoxicam concentrations after single and multiple oral doses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[μg] / [ml],9.67,214592,DB00554,Piroxicam
,2788089,t1/2,"AUC within a dosing interval at steady-state was 262.2 +/- 67.0 micrograms x h/ml, Cminss was 9.67 +/- 3.25 micrograms/ml, and t1/2 averaged 74.2 +/- 13.3 h.",Plasma tenoxicam concentrations after single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),h,74.2,214593,DB00554,Piroxicam
,2788089,accumulation ratio,The average fluctuation during multiple-dose administration was 26.8 +/- 8.0% and the accumulation ratio was 5.82 +/- 0.60.,Plasma tenoxicam concentrations after single and multiple oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),,5.82,214594,DB00554,Piroxicam
,24524289,C(max),"The pharmacokinetics parameters of the rats were C(max) 1065.91 ± 224.90 and 1855.22 ± 748.25 ngmL(-1), T(max) were 2.5 ± 0.4 h and 1.8 ± 0.5 h, and AUC(0∼t) were 5316.35 ± 323.62 and 7758.07 ± 241.57 ngmL(-1) h, respectively.",Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24524289/),1/[ngml],1065.91,215391,DB00554,Piroxicam
,24524289,C(max),"The pharmacokinetics parameters of the rats were C(max) 1065.91 ± 224.90 and 1855.22 ± 748.25 ngmL(-1), T(max) were 2.5 ± 0.4 h and 1.8 ± 0.5 h, and AUC(0∼t) were 5316.35 ± 323.62 and 7758.07 ± 241.57 ngmL(-1) h, respectively.",Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24524289/),1/[ngml],1855.22,215392,DB00554,Piroxicam
,24524289,T(max),"The pharmacokinetics parameters of the rats were C(max) 1065.91 ± 224.90 and 1855.22 ± 748.25 ngmL(-1), T(max) were 2.5 ± 0.4 h and 1.8 ± 0.5 h, and AUC(0∼t) were 5316.35 ± 323.62 and 7758.07 ± 241.57 ngmL(-1) h, respectively.",Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24524289/),h,2.5,215393,DB00554,Piroxicam
,24524289,T(max),"The pharmacokinetics parameters of the rats were C(max) 1065.91 ± 224.90 and 1855.22 ± 748.25 ngmL(-1), T(max) were 2.5 ± 0.4 h and 1.8 ± 0.5 h, and AUC(0∼t) were 5316.35 ± 323.62 and 7758.07 ± 241.57 ngmL(-1) h, respectively.",Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24524289/),h,1.8,215394,DB00554,Piroxicam
,24524289,AUC(0∼t),"The pharmacokinetics parameters of the rats were C(max) 1065.91 ± 224.90 and 1855.22 ± 748.25 ngmL(-1), T(max) were 2.5 ± 0.4 h and 1.8 ± 0.5 h, and AUC(0∼t) were 5316.35 ± 323.62 and 7758.07 ± 241.57 ngmL(-1) h, respectively.",Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24524289/),[h] / [ngml],5316.35,215395,DB00554,Piroxicam
,24524289,AUC(0∼t),"The pharmacokinetics parameters of the rats were C(max) 1065.91 ± 224.90 and 1855.22 ± 748.25 ngmL(-1), T(max) were 2.5 ± 0.4 h and 1.8 ± 0.5 h, and AUC(0∼t) were 5316.35 ± 323.62 and 7758.07 ± 241.57 ngmL(-1) h, respectively.",Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24524289/),[h] / [ngml],7758.07,215396,DB00554,Piroxicam
,24524289,relative bioavailability,"Calculated by AUC(0∼∞), the relative bioavailability of Lornoxicam S-SMEDDS was 151.69 ± 15.32%.",Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24524289/),%,151.69,215397,DB00554,Piroxicam
,3879481,time for peak plasma drug levels,"The rate of absorption was slower with post-prandial than with pre-prandial administration, resulting in a significantly later time for peak plasma drug levels (4.1 h compared to 1.3 h).",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,4.1,216231,DB00554,Piroxicam
,3879481,time for peak plasma drug levels,"The rate of absorption was slower with post-prandial than with pre-prandial administration, resulting in a significantly later time for peak plasma drug levels (4.1 h compared to 1.3 h).",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,1.3,216232,DB00554,Piroxicam
,3879481,t1/2,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,0.47,216233,DB00554,Piroxicam
,3879481,t1/2,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,0.18,216234,DB00554,Piroxicam
,3879481,peak time,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,4.7,216235,DB00554,Piroxicam
,3879481,peak time,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,2.3,216236,DB00554,Piroxicam
,3879481,peak level,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),[μg] / [ml],4.2,216237,DB00554,Piroxicam
,3879481,peak level,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),[μg] / [ml],5.1,216238,DB00554,Piroxicam
,14602190,Cmax,"The apparent rate of absorption of piroxicam from GL (Cmax=2.64 micrograms/ml, tmax=82.5 min) was significantly higher than that of the PP (Cmax=0.999 micrograms/ml, tmax=144 min) (P<0.05) and similar to that of CD (Cmax=2.44 micrograms/ml, tmax=120 min) (P>0.05).",Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602190/),[μg] / [ml],2.64,216352,DB00554,Piroxicam
,14602190,tmax,"The apparent rate of absorption of piroxicam from GL (Cmax=2.64 micrograms/ml, tmax=82.5 min) was significantly higher than that of the PP (Cmax=0.999 micrograms/ml, tmax=144 min) (P<0.05) and similar to that of CD (Cmax=2.44 micrograms/ml, tmax=120 min) (P>0.05).",Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602190/),min,82.5,216353,DB00554,Piroxicam
,14602190,Cmax,"The apparent rate of absorption of piroxicam from GL (Cmax=2.64 micrograms/ml, tmax=82.5 min) was significantly higher than that of the PP (Cmax=0.999 micrograms/ml, tmax=144 min) (P<0.05) and similar to that of CD (Cmax=2.44 micrograms/ml, tmax=120 min) (P>0.05).",Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602190/),[μg] / [ml],0.999,216354,DB00554,Piroxicam
,14602190,tmax,"The apparent rate of absorption of piroxicam from GL (Cmax=2.64 micrograms/ml, tmax=82.5 min) was significantly higher than that of the PP (Cmax=0.999 micrograms/ml, tmax=144 min) (P<0.05) and similar to that of CD (Cmax=2.44 micrograms/ml, tmax=120 min) (P>0.05).",Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602190/),min,144,216355,DB00554,Piroxicam
,14602190,Cmax,"The apparent rate of absorption of piroxicam from GL (Cmax=2.64 micrograms/ml, tmax=82.5 min) was significantly higher than that of the PP (Cmax=0.999 micrograms/ml, tmax=144 min) (P<0.05) and similar to that of CD (Cmax=2.44 micrograms/ml, tmax=120 min) (P>0.05).",Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602190/),[μg] / [ml],2.44,216356,DB00554,Piroxicam
,14602190,tmax,"The apparent rate of absorption of piroxicam from GL (Cmax=2.64 micrograms/ml, tmax=82.5 min) was significantly higher than that of the PP (Cmax=0.999 micrograms/ml, tmax=144 min) (P<0.05) and similar to that of CD (Cmax=2.44 micrograms/ml, tmax=120 min) (P>0.05).",Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602190/),min,120,216357,DB00554,Piroxicam
,14602190,relative bioavailability,"The relative bioavailability values as the ratios of mean total AUC for GL relative to PP and CD, were 221 and 98.6%.",Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602190/),%,221,216358,DB00554,Piroxicam
,14602190,relative bioavailability,"The relative bioavailability values as the ratios of mean total AUC for GL relative to PP and CD, were 221 and 98.6%.",Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14602190/),%,98.6,216359,DB00554,Piroxicam
,3190995,Steady-state concentrations,"3. Steady-state concentrations of tenoxicam decreased significantly from 10.4 +/- 1.5 to 4.5 +/- 1.6 micrograms ml-1 in the presence of chronic, high-dose aspirin treatment.",The effect of concurrent aspirin upon plasma concentrations of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190995/),,10.4,219117,DB00554,Piroxicam
,3190995,Steady-state concentrations,"3. Steady-state concentrations of tenoxicam decreased significantly from 10.4 +/- 1.5 to 4.5 +/- 1.6 micrograms ml-1 in the presence of chronic, high-dose aspirin treatment.",The effect of concurrent aspirin upon plasma concentrations of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190995/),,4.5,219118,DB00554,Piroxicam
,8352822,flow rate,The flow rate was 1 ml/min and the effluent was monitored at 365 nm with 0.02 AUFS (absorbance units full scale).,"High-performance liquid chromatographic analysis of piroxicam and tenoxicam in plasma, blood and buffer solution. Application to pharmacokinetic studies in small laboratory animals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352822/),[ml] / [min],1,220013,DB00554,Piroxicam
,28283842,percent drug released,"The chosen formula (F2, DC 24 mg, F-Melt 88.4 mg, and crospovidone 5 mg) exhibited the shortest in vitro (18 s) and in vivo DT (13 s), and the percent drug released after Q6min was 95.90%.",A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283842/),%,95.90,224611,DB00554,Piroxicam
,28283842,maximum drug plasma concentrations (Cmax),"Following administration of F2 and Zeficam®, the respective maximum drug plasma concentrations (Cmax) were 510 and 532.5 ng/mL, at times (Tmax) of 1 and 2.5 h, of mean residence times (MRTs) of 12.25 and 11.35 h and of areas under the plasma curve [AUC(0-24)] of 5080.253 and 4815.775 ng/h/mL.",A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283842/),[ng] / [ml],510,224612,DB00554,Piroxicam
,28283842,maximum drug plasma concentrations (Cmax),"Following administration of F2 and Zeficam®, the respective maximum drug plasma concentrations (Cmax) were 510 and 532.5 ng/mL, at times (Tmax) of 1 and 2.5 h, of mean residence times (MRTs) of 12.25 and 11.35 h and of areas under the plasma curve [AUC(0-24)] of 5080.253 and 4815.775 ng/h/mL.",A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283842/),[ng] / [ml],532.5,224613,DB00554,Piroxicam
,28283842,times (Tmax),"Following administration of F2 and Zeficam®, the respective maximum drug plasma concentrations (Cmax) were 510 and 532.5 ng/mL, at times (Tmax) of 1 and 2.5 h, of mean residence times (MRTs) of 12.25 and 11.35 h and of areas under the plasma curve [AUC(0-24)] of 5080.253 and 4815.775 ng/h/mL.",A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283842/),h,1,224614,DB00554,Piroxicam
,28283842,times (Tmax),"Following administration of F2 and Zeficam®, the respective maximum drug plasma concentrations (Cmax) were 510 and 532.5 ng/mL, at times (Tmax) of 1 and 2.5 h, of mean residence times (MRTs) of 12.25 and 11.35 h and of areas under the plasma curve [AUC(0-24)] of 5080.253 and 4815.775 ng/h/mL.",A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283842/),h,2.5,224615,DB00554,Piroxicam
,28283842,mean residence times (MRTs),"Following administration of F2 and Zeficam®, the respective maximum drug plasma concentrations (Cmax) were 510 and 532.5 ng/mL, at times (Tmax) of 1 and 2.5 h, of mean residence times (MRTs) of 12.25 and 11.35 h and of areas under the plasma curve [AUC(0-24)] of 5080.253 and 4815.775 ng/h/mL.",A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283842/),h,12.25,224616,DB00554,Piroxicam
,28283842,mean residence times (MRTs),"Following administration of F2 and Zeficam®, the respective maximum drug plasma concentrations (Cmax) were 510 and 532.5 ng/mL, at times (Tmax) of 1 and 2.5 h, of mean residence times (MRTs) of 12.25 and 11.35 h and of areas under the plasma curve [AUC(0-24)] of 5080.253 and 4815.775 ng/h/mL.",A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283842/),h,11.35,224617,DB00554,Piroxicam
,28283842,areas under the plasma curve [AUC(0-24)],"Following administration of F2 and Zeficam®, the respective maximum drug plasma concentrations (Cmax) were 510 and 532.5 ng/mL, at times (Tmax) of 1 and 2.5 h, of mean residence times (MRTs) of 12.25 and 11.35 h and of areas under the plasma curve [AUC(0-24)] of 5080.253 and 4815.775 ng/h/mL.",A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283842/),[ng] / [h·ml],5080.253,224618,DB00554,Piroxicam
,28283842,areas under the plasma curve [AUC(0-24)],"Following administration of F2 and Zeficam®, the respective maximum drug plasma concentrations (Cmax) were 510 and 532.5 ng/mL, at times (Tmax) of 1 and 2.5 h, of mean residence times (MRTs) of 12.25 and 11.35 h and of areas under the plasma curve [AUC(0-24)] of 5080.253 and 4815.775 ng/h/mL.",A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283842/),[ng] / [h·ml],4815.775,224619,DB00554,Piroxicam
,28283842,relative bioavailability,FDTs could be considered as promising dosage forms for lornoxicam as they exhibited a short in vivo DT and an increased rate of drug release and attained a relative bioavailability of 105.49%.,A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283842/),%,105.49,224620,DB00554,Piroxicam
,15488057,level,"The mean (95% CI) piroxicam level following 0.4 mg.kg(-1) was 2.90 (2.33-3.54) microg.ml(-1), compared to 5.87 (4.58-7.16) microg.",A pharmacokinetic study of piroxicam in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15488057/),,2,229650,DB00554,Piroxicam
,15488057,level,"The mean (95% CI) piroxicam level following 0.4 mg.kg(-1) was 2.90 (2.33-3.54) microg.ml(-1), compared to 5.87 (4.58-7.16) microg.",A pharmacokinetic study of piroxicam in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15488057/),,5,229651,DB00554,Piroxicam
,2284216,plasma t1/2,Lornoxicam is well absorbed and has a plasma t1/2 in man of 4 hours which is distinctly different from other oxicams.,"Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2284216/),h,4,232281,DB00554,Piroxicam
,10027662,areas under the concentration-time curve (AUC),The median (range) areas under the concentration-time curve (AUC) for (R)-acenocoumarol were 3458 (3035-7312) microg x h 1(-1) in the absence of and 3667 (2907-7741) microg x h 1(-1) in the presence of lornoxicam.,No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027662/),h·μg,3458,233825,DB00554,Piroxicam
,10027662,areas under the concentration-time curve (AUC),The median (range) areas under the concentration-time curve (AUC) for (R)-acenocoumarol were 3458 (3035-7312) microg x h 1(-1) in the absence of and 3667 (2907-7741) microg x h 1(-1) in the presence of lornoxicam.,No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027662/),h·μg,3667,233826,DB00554,Piroxicam
,3602018,plasma half-life,"Steady state plasma isoxicam concentrations varied from 20 micrograms/ml to 130 micrograms/ml, while the plasma half-life varied from 23 hours to 58 hours.",Pharmacokinetics and effects of isoxicam on renal function in patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602018/),h,23,234052,DB00554,Piroxicam
,3602018,plasma half-life,"Steady state plasma isoxicam concentrations varied from 20 micrograms/ml to 130 micrograms/ml, while the plasma half-life varied from 23 hours to 58 hours.",Pharmacokinetics and effects of isoxicam on renal function in patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602018/),h,58,234053,DB00554,Piroxicam
,12887607,bioavailability (F),PIRO is well absorbed in the cat with a median bioavailability (F) of 80% (range 64-124%).,Single dose pharmacokinetics of piroxicam in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887607/),%,80,237605,DB00554,Piroxicam
,12887607,t1/2,The median i.v. t1/2 was 12 h (range 8.6-14 h).,Single dose pharmacokinetics of piroxicam in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887607/),h,12,237606,DB00554,Piroxicam
,12887607,Cmax,The median Cmax was 519 ng/mL with a corresponding Tmax of 3 h.,Single dose pharmacokinetics of piroxicam in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887607/),[ng] / [ml],519,237607,DB00554,Piroxicam
,12887607,Tmax,The median Cmax was 519 ng/mL with a corresponding Tmax of 3 h.,Single dose pharmacokinetics of piroxicam in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12887607/),h,3,237608,DB00554,Piroxicam
,27592284,flow rate,"The separation of both the analytes and internal standard was achieved on Discovery HS C18 column (250mm×4.6mm, 5μm) using Acetonitrile and TFA (0.025%) in the ratio of (65:35V/V) as the mobile phase in isocratic mode at a flow rate of 1ml/min, with a wavelength of 245nm and at a column oven temperature of 25°Cin a short run time of 12min.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ml] / [min],1,237803,DB00554,Piroxicam
,27592284,limits of,"The limits of detection (LLOD) were 5 and 10ng/ml while the limits of quantification (LLOQ) were 10 and 15ng/ml for sorafenib and paclitaxel, respectively.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ng] / [ml],5,237804,DB00554,Piroxicam
,27592284,limits of,"The limits of detection (LLOD) were 5 and 10ng/ml while the limits of quantification (LLOQ) were 10 and 15ng/ml for sorafenib and paclitaxel, respectively.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ng] / [ml],10,237805,DB00554,Piroxicam
,14765798,MTD,The MTD of cisplatin when administered in combination with piroxicam was 50 mg/m2.,Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14765798/),[mg] / [m2],50,240259,DB00554,Piroxicam
,9578191,Cmax,"There were no significant differences in peak plasma concentration, time to peak plasma concentration or area under the plasma concentration-time curve between bleeders or controls for any of the NSAIDs studied, apart from piroxicam Cmax being lower in bleeders at 2.07 mg l(-1) than in controls at 3.21 mg l(-1), mean difference (95% CI) -1.14 (-1.83 - -0.48), P<0.005.",Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578191/),[mg] / [l],2.07,241166,DB00554,Piroxicam
,9578191,Cmax,"There were no significant differences in peak plasma concentration, time to peak plasma concentration or area under the plasma concentration-time curve between bleeders or controls for any of the NSAIDs studied, apart from piroxicam Cmax being lower in bleeders at 2.07 mg l(-1) than in controls at 3.21 mg l(-1), mean difference (95% CI) -1.14 (-1.83 - -0.48), P<0.005.",Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578191/),[mg] / [l],3.21,241167,DB00554,Piroxicam
,1781800,AUC (0-t),The AUC (0-t) was calculated at 1670 +/- 492 ng/ml x h for diclofenac alone and at 1817 +/- 682 ng/ml x h for diclofenac plus sucralfate.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[ng] / [h·ml],1670,245385,DB00554,Piroxicam
,1781800,AUC (0-t),The AUC (0-t) was calculated at 1670 +/- 492 ng/ml x h for diclofenac alone and at 1817 +/- 682 ng/ml x h for diclofenac plus sucralfate.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[ng] / [h·ml],1817,245386,DB00554,Piroxicam
,1781800,AUC (0-t),The mean AUC (0-t) for piroxicam alone was 91 +/- 19 micrograms/ml x h whilst that for piroxicam plus sucralfate was 91 +/- 20 micrograms/ml x h.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[μg] / [h·ml],91,245387,DB00554,Piroxicam
,1781800,AUC (0-t),The mean AUC (0-t) for piroxicam alone was 91 +/- 19 micrograms/ml x h whilst that for piroxicam plus sucralfate was 91 +/- 20 micrograms/ml x h.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[μg] / [h·ml],91,245388,DB00554,Piroxicam
,1781800,relative bioavailability,"The mean relative bioavailability was 116% for diclofenac plus sucralfate compared to diclofenac alone, and 100% for piroxicam plus sucralfate compared to piroxicam alone.",Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),%,116,245389,DB00554,Piroxicam
,1781800,relative bioavailability,"The mean relative bioavailability was 116% for diclofenac plus sucralfate compared to diclofenac alone, and 100% for piroxicam plus sucralfate compared to piroxicam alone.",Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),%,100,245390,DB00554,Piroxicam
,2783182,plasma half-life (1/2),The plasma half-life (1/2) of piroxicam in male rats was about 8.3 h and it was increased to 20.74 h by cimetidine pretreatment.,Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783182/),h,8.3,245393,DB00554,Piroxicam
,2783182,plasma half-life (1/2),The plasma half-life (1/2) of piroxicam in male rats was about 8.3 h and it was increased to 20.74 h by cimetidine pretreatment.,Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783182/),h,20.74,245394,DB00554,Piroxicam
,2783182,t1/2,The t1/2 of piroxicam was increased from 37.36 to 52.86 h with cimetidine administration.,Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783182/),h,37.36,245395,DB00554,Piroxicam
,2783182,t1/2,The t1/2 of piroxicam was increased from 37.36 to 52.86 h with cimetidine administration.,Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2783182/),h,52.86,245396,DB00554,Piroxicam
,8148224,Cmax,"Cmax was increased significantly when tenoxicam was given with probenecid (2.8 micrograms ml-1 alone, 3.5 micrograms ml-1 after probenecid; P < 0.005).",Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148224/),[μg] / [ml],2.8,246855,DB00554,Piroxicam
,8148224,Cmax,"Cmax was increased significantly when tenoxicam was given with probenecid (2.8 micrograms ml-1 alone, 3.5 micrograms ml-1 after probenecid; P < 0.005).",Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148224/),[μg] / [ml],3.5,246856,DB00554,Piroxicam
,3677504,disappearance t 1/2,"The calculated isoxicam disappearance t 1/2 of 30 +/- 19.1 h in these patients was not different from the mean value of 31 +/- 5.7 h obtained in 10 normal subjects studied earlier by our group; however, interindividual variation was larger.",Pharmacokinetic disposition of isoxicam in hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677504/),h,30,248912,DB00554,Piroxicam
,3677504,disappearance t 1/2,"The calculated isoxicam disappearance t 1/2 of 30 +/- 19.1 h in these patients was not different from the mean value of 31 +/- 5.7 h obtained in 10 normal subjects studied earlier by our group; however, interindividual variation was larger.",Pharmacokinetic disposition of isoxicam in hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677504/),h,31,248913,DB00554,Piroxicam
,3677504,lag time,No differences in lag time (0.42 +/- 0.3 vs 0.49 +/- .2 h) or time to peak concentration (9.0 +/- 2.5 vs 10.0 +/- 2.9 h) were observed.,Pharmacokinetic disposition of isoxicam in hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677504/),h,0.42,248914,DB00554,Piroxicam
,3677504,lag time,No differences in lag time (0.42 +/- 0.3 vs 0.49 +/- .2 h) or time to peak concentration (9.0 +/- 2.5 vs 10.0 +/- 2.9 h) were observed.,Pharmacokinetic disposition of isoxicam in hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677504/),h,0.49,248915,DB00554,Piroxicam
,3677504,time to peak concentration,No differences in lag time (0.42 +/- 0.3 vs 0.49 +/- .2 h) or time to peak concentration (9.0 +/- 2.5 vs 10.0 +/- 2.9 h) were observed.,Pharmacokinetic disposition of isoxicam in hepatic cirrhosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677504/),h,9.0,248916,DB00554,Piroxicam
,3677504,time to peak concentration,No differences in lag time (0.42 +/- 0.3 vs 0.49 +/- .2 h) or time to peak concentration (9.0 +/- 2.5 vs 10.0 +/- 2.9 h) were observed.,Pharmacokinetic disposition of isoxicam in hepatic cirrhosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677504/),h,10.0,248917,DB00554,Piroxicam
,3677504,Plasma protein binding,"Plasma protein binding of isoxicam studied by equilibrium dialysis was 80 +/- 16% in the cirrhotic patients compared with 96 +/- 1.4% in the normal volunteers (p less than 0.02), again with larger interindividual variation noted in patients with cirrhosis.",Pharmacokinetic disposition of isoxicam in hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677504/),%,80,248918,DB00554,Piroxicam
,3677504,Plasma protein binding,"Plasma protein binding of isoxicam studied by equilibrium dialysis was 80 +/- 16% in the cirrhotic patients compared with 96 +/- 1.4% in the normal volunteers (p less than 0.02), again with larger interindividual variation noted in patients with cirrhosis.",Pharmacokinetic disposition of isoxicam in hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677504/),%,96,248919,DB00554,Piroxicam
,2887185,half-life,"2 After a single oral dose, isoxicam was slowly absorbed and eliminated (half-life ranging from 10.5 to 53.9 h).",Pharmacokinetics of isoxicam in hepatic disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887185/),h,10.5 to 53.9,249058,DB00554,Piroxicam
,2887185,elimination half-life,"The mean elimination half-life of isoxicam in five patients was 42.6 +/- 4.5 h, a value which was not statistically different from that obtained in the single dose study.",Pharmacokinetics of isoxicam in hepatic disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887185/),h,42.6,249059,DB00554,Piroxicam
,3879831,peak plasma level,Approximately five-fold accumulation was found at steady-state (mean peak plasma level 2.6 micrograms/ml for a single dose against 12.4 micrograms/ml at steady-state).,Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879831/),[μg] / [ml],2.6,251149,DB00554,Piroxicam
,3879831,peak plasma level,Approximately five-fold accumulation was found at steady-state (mean peak plasma level 2.6 micrograms/ml for a single dose against 12.4 micrograms/ml at steady-state).,Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879831/),[μg] / [ml],12.4,251150,DB00554,Piroxicam
,3879831,plasma level at steady-state,Mean pre-dose plasma level at steady-state was 9.6 micrograms/ml with a coefficient of variation of 11%.,Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879831/),[μg] / [ml],9.6,251151,DB00554,Piroxicam
,15127622,flow-rate,The mobile phase consisted of methanol-water-formic acid (80:20:0.5) at a flow-rate of 0.7 mL.min-1.,[Determination of lornoxicam in human plasma by LC/MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15127622/),[ml] / [min],0.7,251867,DB00554,Piroxicam
,15127622,T1/2,"The main parameters obtained after an oral dose of 8 mg lornoxicam to 18 Chinese male volunteers were as follows: the value of T1/2 was (4.7 +/- 1.1) h, AUC0-infinity was found to be (5.5 +/- 2.4) mg.h.L-1.",[Determination of lornoxicam in human plasma by LC/MS/MS]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15127622/),h,4.7,251868,DB00554,Piroxicam
,15127622,AUC0-infinity,"The main parameters obtained after an oral dose of 8 mg lornoxicam to 18 Chinese male volunteers were as follows: the value of T1/2 was (4.7 +/- 1.1) h, AUC0-infinity was found to be (5.5 +/- 2.4) mg.h.L-1.",[Determination of lornoxicam in human plasma by LC/MS/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15127622/),[h·mg] / [l],5.5,251869,DB00554,Piroxicam
,15127622,T1/2,"However, T1/2 of 105 h and AUC0-infinity of 189.5 mg.h.L-1 were obtained for another volunteer.",[Determination of lornoxicam in human plasma by LC/MS/MS]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15127622/),h,105,251870,DB00554,Piroxicam
,15127622,AUC0-infinity,"However, T1/2 of 105 h and AUC0-infinity of 189.5 mg.h.L-1 were obtained for another volunteer.",[Determination of lornoxicam in human plasma by LC/MS/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15127622/),[h·mg] / [l],189.5,251871,DB00554,Piroxicam
,2670397,elimination half-life,"Even though diclofenac has a relatively short elimination half-life in plasma (1.5 hours), it persists in synovial fluid.",Diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670397/),h,1.5,252500,DB00554,Piroxicam
,18992346,AUC(0-infinity),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[h·μg] / [ml],256,252735,DB00554,Piroxicam
,18992346,AUC(0-infinity),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[h·μg] / [ml],150,252736,DB00554,Piroxicam
,18992346,AUC(0-infinity),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[h·μg] / [ml],169,252737,DB00554,Piroxicam
,18992346,half-life time (t1/2),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),h,102,252738,DB00554,Piroxicam
,18992346,half-life time (t1/2),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),h,56,252739,DB00554,Piroxicam
,18992346,half-life time (t1/2),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),h,64,252740,DB00554,Piroxicam
,18992346,C(max),"Non-significant differences were observed in C(max) 1.9 (1.8-2.9) vs. 2.4 (1.7-3.4), 2.5 (1.6-2.9) microg/mL or in according to CYP2C8 alleles presence.",Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[μg] / [ml],1.9,252741,DB00554,Piroxicam
,18992346,C(max),"Non-significant differences were observed in C(max) 1.9 (1.8-2.9) vs. 2.4 (1.7-3.4), 2.5 (1.6-2.9) microg/mL or in according to CYP2C8 alleles presence.",Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[μg] / [ml],2.4,252742,DB00554,Piroxicam
,18992346,C(max),"Non-significant differences were observed in C(max) 1.9 (1.8-2.9) vs. 2.4 (1.7-3.4), 2.5 (1.6-2.9) microg/mL or in according to CYP2C8 alleles presence.",Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[μg] / [ml],2.5,252743,DB00554,Piroxicam
,18479176,AUCinfinity ratio,"The AUCinfinity ratio (90% CI) was 1.07 (0.94, 1.20) for lornoxicam-QR/lornoxicam-ST and 1.10 (0.97, 1.24) for lornoxicam-QR/lornoxicam-IM.","Comparative bioavailability of lornoxicam as single doses of quick-release tablet, standard tablet and intramuscular injection: a randomized, open-label, crossover phase I study in healthy volunteers. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479176/),,1.07,254744,DB00554,Piroxicam
,18479176,AUCinfinity ratio,"The AUCinfinity ratio (90% CI) was 1.07 (0.94, 1.20) for lornoxicam-QR/lornoxicam-ST and 1.10 (0.97, 1.24) for lornoxicam-QR/lornoxicam-IM.","Comparative bioavailability of lornoxicam as single doses of quick-release tablet, standard tablet and intramuscular injection: a randomized, open-label, crossover phase I study in healthy volunteers. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479176/),,1.,254745,DB00554,Piroxicam
,1425878,half-life (t1/2),"After a single dose, tenoxicam had a half-life (t1/2) of 33 h, an apparent clearance (CL.f-1) of 4.3 ml.min-1, and an apparent volume of distribution (Vz.f-1) of 11.81.",The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425878/),h,33,255615,DB00554,Piroxicam
,1425878,apparent clearance (CL.f-1),"After a single dose, tenoxicam had a half-life (t1/2) of 33 h, an apparent clearance (CL.f-1) of 4.3 ml.min-1, and an apparent volume of distribution (Vz.f-1) of 11.81.",The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425878/),[ml] / [min],4.3,255616,DB00554,Piroxicam
,1425878,apparent volume of distribution (Vz.f-1),"After a single dose, tenoxicam had a half-life (t1/2) of 33 h, an apparent clearance (CL.f-1) of 4.3 ml.min-1, and an apparent volume of distribution (Vz.f-1) of 11.81.",The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425878/),,11.81,255617,DB00554,Piroxicam
,1425878,maximum tenoxicam concentration (Cmax),The maximum tenoxicam concentration (Cmax) was 4.3 mg.l-1 at a median tmax of 1.7 h.,The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425878/),[mg] / [l],4.3,255618,DB00554,Piroxicam
,1425878,tmax,The maximum tenoxicam concentration (Cmax) was 4.3 mg.l-1 at a median tmax of 1.7 h.,The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425878/),h,1.7,255619,DB00554,Piroxicam
,3266152,elimination half-life,The elimination half-life of tenoxicam ranged from 44 to 132 h (mean 71.9 h) with no significant difference between the single and multiple dosage regimens.,Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),h,71.9,255927,DB00554,Piroxicam
,3266152,maximum plasma concentrations,"Tenoxicam reached maximum plasma concentrations after 1.4 and 1.1 h, with values of 3.6 and 15.5 micrograms.",Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),μg,3.6,255928,DB00554,Piroxicam
,3266152,maximum plasma concentrations,"Tenoxicam reached maximum plasma concentrations after 1.4 and 1.1 h, with values of 3.6 and 15.5 micrograms.",Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),μg,15.5,255929,DB00554,Piroxicam
,3266152,trough,The corresponding trough values (24-h values) were 1.8 and 11.7 micrograms.,Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),μg,1.8,255930,DB00554,Piroxicam
,3266152,trough,The corresponding trough values (24-h values) were 1.8 and 11.7 micrograms.,Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),μg,11.7,255931,DB00554,Piroxicam
,3266152,accumulation ratio,A mean accumulation ratio of 5.1 was calculated.,Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),,5.1,255932,DB00554,Piroxicam
,3580513,area under the isoxicam plasma concentration-time curve (AUC infinity),The area under the isoxicam plasma concentration-time curve (AUC infinity) increased from 389 +/- 66 to 464 +/- 62 micrograms h ml-1 (+/- SEM) (p less than 0.05) after treatment with phenytoin.,The effect of administration of phenytoin on the pharmacokinetics of isoxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580513/),[h·μg] / [ml],389,265379,DB00554,Piroxicam
,3580513,area under the isoxicam plasma concentration-time curve (AUC infinity),The area under the isoxicam plasma concentration-time curve (AUC infinity) increased from 389 +/- 66 to 464 +/- 62 micrograms h ml-1 (+/- SEM) (p less than 0.05) after treatment with phenytoin.,The effect of administration of phenytoin on the pharmacokinetics of isoxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580513/),[h·μg] / [ml],464,265380,DB00554,Piroxicam
,3580513,absorption rate constant,This increase was due to an increase in isoxicam bioavailability; the absorption rate constant for isoxicam increased correspondingly from 0.34 +/- 0.06 to 1.16 +/- 0.38 h-1 (p less than 0.05).,The effect of administration of phenytoin on the pharmacokinetics of isoxicam. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580513/),1/[h],0.34,265381,DB00554,Piroxicam
,3580513,absorption rate constant,This increase was due to an increase in isoxicam bioavailability; the absorption rate constant for isoxicam increased correspondingly from 0.34 +/- 0.06 to 1.16 +/- 0.38 h-1 (p less than 0.05).,The effect of administration of phenytoin on the pharmacokinetics of isoxicam. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580513/),1/[h],1.16,265382,DB00554,Piroxicam
,16169293,recoveries,"The recoveries of piroxicam, meloxicam and tenoxicam ranged from 78.3 to 87.1%, with that of isoxicam being 59.7%.","Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169293/),%,78.3 to 87.1,268710,DB00554,Piroxicam
,16169293,recoveries,"The recoveries of piroxicam, meloxicam and tenoxicam ranged from 78.3 to 87.1%, with that of isoxicam being 59.7%.","Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169293/),%,59.7,268711,DB00554,Piroxicam
